Kazuma Ohyashiki

Q: What Schools Are Affiliated With Kazuma Ohyashiki

Kazuma Ohyashiki is affiliated with the following schools: University of Tokyo, Stanford University, Tokyo Medical University

Kazuma Ohyashiki's AcademicInfluence.com Rankings

Kazuma Ohyashiki

Computer Science

#7069

World Rank

#7446

Historical Rank

Computational Linguistics

#1345

World Rank

#1360

Historical Rank

Machine Learning

#2496

World Rank

#2529

Historical Rank

Artificial Intelligence

#2783

World Rank

#2827

Historical Rank

computer-science Degrees

Download Badge

Computer Science

Kazuma Ohyashiki's Degrees

PhD Computer Science University of Tokyo
Masters Computer Science University of Tokyo
Bachelors Computer Science University of Tokyo

Similar Degrees You Can Earn

Why Is Kazuma Ohyashiki Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Kazuma Ohyashiki's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

International scoring system for evaluating prognosis in myelodysplastic syndromes. (1997) (4221)
New comprehensive cytogenetic scoring system for primary myelodysplastic syndromes (MDS) and oligoblastic acute myeloid leukemia after MDS derived from an international database merge. (2012) (587)
Fusion of the nucleoporin gene NUP98 to HOXA9 by the chromosome translocation t(7;11)(p15;p15) in human myeloid leukaemia (1996) (528)
The t(7;11)(p15;p15) translocation in acute myeloid leukaemia fuses the genes for nucleoporin NUP96 and class I homeoprotein HOXA9 (1996) (469)
Exosomal miR-135b shed from hypoxic multiple myeloma cells enhances angiogenesis by targeting factor-inhibiting HIF-1. (2014) (466)
Leukemia cell to endothelial cell communication via exosomal miRNAs (2013) (405)
Exosomes Derived from Hypoxic Leukemia Cells Enhance Tube Formation in Endothelial Cells* (2013) (295)
Down-Regulation of miR-92 in Human Plasma Is a Novel Marker for Acute Leukemia Patients (2009) (288)
Telomeric length and telomerase activity vary with age in peripheral blood cells obtained from normal individuals (1998) (250)
Hlf, a novel hepatic bZIP protein, shows altered DNA-binding properties following fusion to E2A in t(17;19) acute lymphoblastic leukemia. (1992) (227)
Tumor‐related leukocytosis is linked with poor prognosis in patients with lung carcinoma (2001) (205)
Activity of a novel G-quadruplex-interactive telomerase inhibitor, telomestatin (SOT-095), against human leukemia cells: involvement of ATM-dependent DNA damage response pathways (2003) (204)
Telomerase inhibition with a novel G-quadruplex-interactive agent, telomestatin: in vitro and in vivo studies in acute leukemia (2006) (198)
Genetic variants in C5 and poor response to eculizumab. (2014) (185)
The Wilms’ tumor gene WT1 is a good marker for diagnosis of disease progression of myelodysplastic syndromes (1999) (180)
Cytogenetic studies of tumor tissue from patients with nonfamilial renal cell carcinoma. (1986) (178)
Clinical implications of chromosomal abnormalities in 401 patients with myelodysplastic syndromes: a multicentric study in Japan. (1993) (174)
Enhancement of intracellular signaling associated with hematopoietic progenitor cell survival in response to SDF-1/CXCL12 in synergy with other cytokines. (2002) (172)
Telomeres and telomerase in hematologic neoplasia (2002) (148)
Telomere shortening associated with disease evolution patterns in myelodysplastic syndromes. (1994) (145)
Discontinuation of imatinib in Japanese patients with chronic myeloid leukemia (2011) (141)
The oral iron chelator deferasirox represses signaling through the mTOR in myeloid leukemia cells by enhancing expression of REDD1 (2009) (131)
Impact of adjunct cytogenetic abnormalities for prognostic stratification in patients with myelodysplastic syndrome and deletion 5q (2011) (121)
Telomere stability is frequently impaired in high-risk groups of patients with myelodysplastic syndromes. (1999) (106)
Vitamin K2 induces autophagy and apoptosis simultaneously in leukemia cells (2008) (100)
Telomerase inhibition enhances apoptosis in human acute leukemia cells: possibility of antitelomerase therapy (2003) (99)
Fusion of TEL/ETV6 to a novel ACS2 in myelodysplastic syndrome and acute myelogenous leukemia with t(5;12)(q31;p13) (1999) (96)
Cytological detection of telomerase activity using an in situ telomeric repeat amplification protocol assay. (1997) (93)
Clinical Impact of Down-Regulated Plasma miR-92a Levels in Non-Hodgkin's Lymphoma (2011) (92)
Tyrosine phosphorylation and activation of focal adhesion kinase (p125FAK) by BCR-ABL oncoprotein. (1995) (92)
Clinical implications of telomerase activity levels in acute leukemia. (1997) (89)
Telomerase activity and cytogenetic changes in chronic myeloid leukemia with disease progression (1997) (89)
Single-translocation and double-chimeric transcripts: detection of NUP98-HOXA9 in myeloid leukemias with HOXA11 or HOXA13 breaks of the chromosomal translocation t(7;11)(p15;p15). (2002) (87)
MEIS1 and HOXA7 genes in human acute myeloid leukemia. (2000) (82)
Stromal cell-derived factor-1alpha/CXCL12-induced chemotaxis of T cells involves activation of the RasGAP-associated docking protein p62Dok-1. (2005) (77)
Imatinib mesylate-induced hepato-toxicity in chronic myeloid leukemia demonstrated focal necrosis resembling acute viral hepatitis (2002) (75)
Methylation of p15INK4b and E-cadherin genes is independently correlated with poor prognosis in acute myeloid leukemia (2005) (74)
Replenishing exosomes from older bone marrow stromal cells with miR-340 inhibits myeloma-related angiogenesis. (2017) (69)
Impact on cell to plasma ratio of miR-92a in patients with acute leukemia: in vivo assessment of cell to plasma ratio of miR-92a (2010) (69)
Expression profile of a gamma-deletion variant of the human telomerase reverse transcriptase gene. (2003) (67)
Telomerase activity in lung cancer cells obtained from bronchial washings. (1998) (64)
Molecular mechanisms of resistance of leukemia to imatinib mesylate. (2004) (64)
Transcriptional profiling of Epstein–Barr virus (EBV) genes and host cellular genes in nasal NK/T-cell lymphoma and chronic active EBV infection (2006) (64)
The expression pattern of erythrocyte/megakaryocyte-related transcription factors GATA-1 and the stem cell leukemia gene correlates with hematopoietic differentiation and is associated with outcome of acute myeloid leukemia. (1995) (63)
Cyclosporin A therapy for patients with myelodysplastic syndrome: multicenter pilot studies in Japan. (2003) (62)
Apoptosis/differentiation-inducing effects of vitamin K2 on HL-60 cells: dichotomous nature of vitamin K2 in leukemia cells (2001) (61)
Japanese epidemiological survey with consensus statement on Japanese guidelines for treatment of iron overload in bone marrow failure syndromes (2008) (61)
Downregulated plasma miR-92a levels have clinical impact on multiple myeloma and related disorders (2012) (60)
Randomized trial of cefepime monotherapy or cefepime in combination with amikacin as empirical therapy for febrile neutropenia. (2004) (59)
Methylation of p15(INK4b) and E-cadherin genes is independently correlated with poor prognosis in acute myeloid leukemia. (2005) (59)
Human cord blood-derived primitive progenitors are enriched in CD34+c-kit− cells: correlation between long-term culture-initiating cells and telomerase expression (1998) (58)
Safety and efficacy of the terminal complement inhibitor eculizumab in Japanese patients with paroxysmal nocturnal hemoglobinuria: the AEGIS Clinical Trial (2011) (56)
Clinical relevance of plasma miR-106b levels in patients with chronic obstructive pulmonary disease. (2013) (56)
A G-quadruplex-interactive agent, telomestatin (SOT-095), induces telomere shortening with apoptosis and enhances chemosensitivity in acute myeloid leukemia. (2004) (56)
Exosomes promote bone marrow angiogenesis in hematologic neoplasia: the role of hypoxia (2016) (55)
The relationship between telomere length and therapy‐associated cytogenetic responses in patients with chronic myeloid leukemia (1997) (54)
Efficacy of SCH66336, a farnesyl transferase inhibitor, in conjunction with imatinib against BCR-ABL-positive cells. (2003) (54)
The JAK2 V617F tyrosine kinase mutation in myelodysplastic syndromes (MDS) developing myelofibrosis indicates the myeloproliferative nature in a subset of MDS patients (2005) (53)
Lack of mutations of the human telomerase RNA gene (hTERC) in myelodysplastic syndrome. (2005) (53)
Hypermethylation of p16INK4a and p15INK4b genes in non-small cell lung cancer (2001) (53)
Establishment of a novel heterotransplantable acute lymphoblastic leukemia cell line with a t(17;19) chromosomal translocation the growth of which is inhibited by interleukin-3. (1991) (52)
Inhibition of human telomerase enhances the effect of chemotherapeutic agents in lung cancer cells. (2002) (51)
Variant Ph1 translocations in CML and their incidence, including two cases with sequential lymphoid and myeloid crises. (1982) (50)
Antitumor effects of a novel phenoxazine derivative on human leukemia cell lines in vitro and in vivo. (2001) (50)
Inhibition of human telomerase enhances the effect of the tyrosine kinase inhibitor, imatinib, in BCR-ABL-positive leukemia cells. (2002) (50)
Clinical and cytogenetic characteristics of myelodysplastic syndromes developing myelofibrosis (1991) (49)
Telomere Dynamics in Myelodysplastic Syndromes and Acute Leukemic Transformation (2001) (49)
Increased natural killer cells and decreased CD3+CD8+CD62L+ T cells in CML patients who sustained complete molecular remission after discontinuation of imatinib (2012) (48)
Monosomal karyotype in MDS: explaining the poor prognosis? (2013) (48)
Shorter halving time of BCR‐ABL1 transcripts is a novel predictor for achievement of molecular responses in newly diagnosed chronic‐phase chronic myeloid leukemia treated with dasatinib: Results of the D‐first study of Kanto CML study group (2015) (48)
Cytogenetic characterization of putative human myeloblastic leukemia cell lines (ML-1, -2, and -3): origin of the cells. (1986) (48)
Speciation of arsenic trioxide penetrates into cerebrospinal fluid in patients with acute promyelocytic leukemia. (2010) (47)
Unbalanced translocation der(1;7)(q10;p10) defines a unique clinicopathological subgroup of myeloid neoplasms (2007) (47)
Association between ApoE phenotypes and telomere erosion in Alzheimer's disease. (2012) (46)
Appelbaum FR, Rowe JM, Radich J, Dick JE. Acute Myeloid Leukemia. Hematology Am Soc Hematol Educ Program. 2001:62-86. PMID: 11722979 (2008) (44)
Nonrandom cytogenetic changes in human acute leukemia and their clinical implications. (1984) (44)
Chlamydia psittaci in ocular adnexal lymphoma: Japanese experience. (2006) (43)
BCL-2 antisense oligonucleotide genasense is active against imatinib-resistant BCR-ABL-positive cells. (2003) (42)
Non‐radioisotopic and Semi‐quantitative Procedure for Terminal Repeat Amplification Protocol (1996) (42)
Detection of telomerase activity in biopsy specimens for diagnosis of biliary tract cancers. (2000) (42)
Interstitial pneumonia induced by imatinib mesylate: pathologic study demonstrates alveolar destruction and fibrosis with eosinophilic infiltration (2004) (41)
Potential molecules implicated in downstream signaling pathways of p185BCR-ABL in Ph+ ALL involve GTPase-activating protein, phospholipase C-gamma 1, and phosphatidylinositol 3'-kinase. (1994) (41)
Molecular genetic, cytogenetic, and immunophenotypic analyses in Castleman's disease of the plasma cell type. (1994) (41)
A Phase I/II study of nilotinib in Japanese patients with imatinib-resistant or -intolerant Ph+ CML or relapsed/refractory Ph+ ALL (2009) (40)
Ecotropic virus integration site-1 gene preferentially expressed in post-myelodysplasia acute myeloid leukemia: possible association with GATA-1, GATA-2, and stem cell leukemia gene expression. (1995) (40)
Vitamin K2-induced antitumor effects via cell-cycle arrest and apoptosis in gastric cancer cell lines. (2006) (40)
Quantitative relationship between functionally active telomerase and major telomerase components (hTERT and hTR) in acute leukaemia cells (2005) (39)
Combination of Ponatinib with Hedgehog Antagonist Vismodegib for Therapy-Resistant BCR-ABL1–Positive Leukemia (2013) (39)
Vitamin K2 therapy for myelodysplastic syndromes (MDS) and post-MDS acute myeloid leukemia: information through a questionnaire survey of multi-center pilot studies in Japan (2000) (39)
The Second Generation of BCR-ABL Tyrosine Kinase Inhibitors (2006) (39)
Rearrangement of chromosome 3 in renal cell carcinoma. (1986) (38)
A safety, pharmacokinetic and pharmacodynamic investigation of deferasirox (Exjade®, ICL670) in patients with transfusion-dependent anemias and iron-overload: a Phase I study in Japan (2008) (38)
Hypermethylation of p16(INK4a) and p15(INK4b) genes in non-small cell lung cancer. (2001) (38)
Efficacy of the dual PI3K and mTOR inhibitor NVP-BEZ235 in combination with nilotinib against BCR-ABL-positive leukemia cells involves the ABL kinase domain mutation (2014) (38)
ELF4/MEF Activates MDM2 Expression and Blocks Oncogene-Induced p16 Activation To Promote Transformation (2009) (37)
Vitamin K2 induces apoptosis of a novel cell line established from a patient with myelodysplastic syndrome in blastic transformation (1999) (36)
Anti-proliferative activity of heat shock protein (Hsp) 90 inhibitors via beta-catenin/TCF7L2 pathway in adult T cell leukemia cells. (2009) (36)
Telomerase activity in human chorionic villi and placenta determined by TRAP and in situ TRAP assay. (1998) (36)
Thrombopoietin induces an SH2-containing protein, CIS1, which binds to Mpl: involvement of the ubiquitin proteosome pathway. (1999) (36)
Apoptosis induction of vitamin K2 in lung carcinoma cell lines: the possibility of vitamin K2 therapy for lung cancer. (2003) (36)
Successful treatment with cyclosporin A for myelodysplastic syndrome with erythroid hypoplasia associated with T‐cell receptor gene rearrangements (2001) (36)
Phase I and II study of azacitidine in Japanese patients with myelodysplastic syndromes (2011) (36)
Sustained upregulation of effector natural killer cells in chronic myeloid leukemia after discontinuation of imatinib (2013) (36)
Comparison of telomerase activity in normal chorionic villi to trophoblastic diseases. (1998) (35)
Phase I/II study of decitabine in patients with myelodysplastic syndrome: A multi‐center study in Japan (2012) (35)
Determination of T-cell receptors of clonal CD8-positive T-cells in myelodysplastic syndrome with erythroid hypoplasia. (2003) (35)
Trisomy of chromosome 8 in myelodysplastic syndrome. Significance of the fluctuating trisomy 8 population. (1992) (34)
Regulatory T cell inhibition by dasatinib is associated with natural killer cell differentiation and a favorable molecular response-The final results of the D-first study. (2018) (34)
The Effect of Anabolic Steroids on Anemia in Myelofibrosis with Myeloid Metaplasia: Retrospective Analysis of 39 Patients in Japan (2007) (34)
Lung Injury Associated with Bortezomib Therapy in Relapsed/Refractory Multiple Myeloma in Japan: A Questionnaire-Based Report from the “Lung Injury by Bortezomib” Joint Committee of the Japanese Society of Hematology and the Japanese Society of Clinical Hematology (2006) (34)
Lineage-specific RUNX2 super-enhancer activates MYC and promotes the development of blastic plasmacytoid dendritic cell neoplasm (2019) (34)
Early cytotoxic lymphocyte expansion contributes to a deep molecular response to dasatinib in patients with newly diagnosed chronic myeloid leukemia in the chronic phase: results of the D‐first study (2015) (34)
Impaired telomere regulation mechanism by TRF1 (telomere-binding protein), but not TRF2 expression, in acute leukemia cells. (2001) (33)
Human herpesvirus 6 reactivation on the 30th day after allogeneic hematopoietic stem cell transplantation can predict grade 2–4 acute graft‐versus‐host disease (2014) (33)
Vitamin K2-induced cell growth inhibition via autophagy formation in cholangiocellular carcinoma cell lines. (2007) (33)
t(7;11)(p15;p15) chronic myeloid leukaemia  developed into blastic transformation showing a novel  NUP98/HOXA11 fusion (2002) (33)
Stromal-cell-derived factor-1/CXCL12-induced chemotaxis of a T cell line involves intracellular signaling through Cbl and Cbl-b and their regulation by Src kinases and CD45. (2006) (33)
Induction of heme oxygenase-1 by cobalt protoporphyrin enhances the antitumour effect of bortezomib in adult T-cell leukaemia cells (2007) (33)
Replication errors in hematological neoplasias: genomic instability in progression of disease is different among different types of leukemia. (1996) (33)
Homeobox genes in hematopoiesis and leukemogenesis. (1998) (32)
Downregulation of Plasma miR-215 in Chronic Myeloid Leukemia Patients with Successful Discontinuation of Imatinib (2016) (32)
Combination of vitamin K2 plus imatinib mesylate enhances induction of apoptosis in small cell lung cancer cell lines. (2005) (31)
Clinico-hematologic Features of Myelodysplastic Syndrome Presenting as Isolated Thrombocytopenia: An Entity with a Relatively Favorable Prognosis (2003) (31)
Telomere dynamics in myelodysplastic syndrome determined by telomere measurement of marrow metaphases. (2003) (31)
Molecular characterization of the recurrent unbalanced translocation der(1;7)(q10;p10). (2003) (30)
Characteristics of Dasatinib- and Imatinib-Resistant Chronic Myelogenous Leukemia Cells (2008) (30)
Telomere Dynamics and Genetic Instability in Disease Progression of Chronic Myeloid Leukemia (2000) (29)
Risk factor analysis in myelodysplastic syndrome patients with del(20q): prognosis revisited. (2006) (29)
A combination of semiquantative telomerase assay and in‐cell telomerase activity measurement using exfoliated urothelial cells for the detection of urothelial neoplasia (1998) (29)
Depsipeptide (FK228) preferentially induces apoptosis in BCR/ABL-expressing cell lines and cells from patients with chronic myelogenous leukemia in blast crisis. (2007) (29)
Ponatinib in Japanese patients with Philadelphia chromosome-positive leukemia, a phase 1/2 study (2017) (29)
Clonal evolution and clinical implications of genetic abnormalities in blastic transformation of chronic myeloid leukaemia (2021) (29)
Interleukin-7 enhances colony growth and induces CD20 antigen of a Ph+ acute lymphoblastic leukemia cell line, OM9;22. (1993) (29)
Age-related decrease of miRNA-92a levels in human CD8+ T-cells correlates with a reduction of naïve T lymphocytes (2011) (28)
Cytogenetic and ultrastructural studies on ten patients with acute promyelocytic leukemia, including one case with a complex translocation. (1985) (28)
Growth inhibitory effects of vitamin K2 on colon cancer cell lines via different types of cell death including autophagy and apoptosis. (2009) (28)
Interim analysis of post-marketing surveillance of eculizumab for paroxysmal nocturnal hemoglobinuria in Japan (2016) (28)
Telomere shortening in leukemic cells is related to their genetic alterations but not replicative capability. (1994) (28)
Seven-year follow-up of patients receiving imatinib for the treatment of newly diagnosed chronic myelogenous leukemia by the TARGET system. (2011) (27)
Use of real-time PCR to monitor human herpesvirus 6 reactivation after allogeneic bone marrow transplantation. (2000) (27)
Quantification of human herpesvirus 6 in healthy volunteers and patients with lymphoproliferative disorders by PCR-ELISA. (1999) (26)
Clinical and cytogenetic findings of myelodysplastic syndromes showing hypocellular bone marrow or minimal dysplasia, in comparison with typical myelodysplastic syndromes. (1993) (26)
Long-term efficacy and safety of eculizumab in Japanese patients with PNH: AEGIS trial (2013) (26)
Hematologic and Cytogenetic Findings in Myelodysplastic Syndromes Treated with Recombinant Human Granulocyte Colony‐stimulating Factor (1989) (26)
Combination of 22-oxa-1,25-dihydroxyvitamin D3, a vitamin D3 derivative, with vitamin K2 (VK2) synergistically enhances cell differentiation but suppresses VK2-inducing apoptosis in HL-60 cells (2002) (26)
Transposition of breakpoint cluster region (3' bcr) in CML cells with variant Philadelphia translocations. (1987) (25)
Detection of telomerase reverse transcriptase mRNA in biopsy specimens and bile for diagnosis of biliary tract cancers. (2001) (25)
Telomere length shortening in patients with dementia with Lewy bodies (2012) (25)
Trisomy 10 in acute myeloid leukemia. (2000) (25)
Myelodysplastic syndrome with chromosome 5 abnormalities: a nationwide survey in Japan (2008) (25)
Bortezomib therapy-related lung disease in Japanese patients with multiple myeloma: Incidence, mortality and clinical characterization (2014) (25)
Problematic WHO reclassification of myelodysplastic syndromes. Members of the International MDS Study Group. (2000) (25)
In situ telomerase activity in pleural effusions: A promising marker for malignancy (2001) (25)
CIS1, a cytokine-inducible SH2 protein, suppresses BCR/ABL-mediated transformation. Involvement of the ubiquitin proteasome pathway. (2001) (25)
Will a peripheral blood (PB) sample yield the same diagnostic and prognostic cytogenetic data as the concomitant bone marrow (BM) in myelodysplasia? (2012) (25)
Jumping translocation of homogeneously staining region and tetraploidy with double minutes in acute myelomonocytic leukemia. (1999) (24)
Clinical evaluation of WT1 mRNA expression levels in peripheral blood and bone marrow in patients with myelodysplastic syndromes (2013) (24)
Pulmonary alveolar proteinosis as a terminal complication in myelodysplastic syndromes: a report of four cases detected on autopsy. (2002) (24)
GATA-1, GATA-2, and stem cell leukemia gene expression in acute myeloid leukemia. (1994) (24)
Immunosuppressive Treatments for Myelodysplastic Syndromes (2003) (24)
Extracellular vesicle-mediated cell–cell communication in haematological neoplasms (2018) (24)
Transfusion-transmitted hepatitis E in a patient with myelodysplastic syndromes. (2014) (23)
Hypermethylation of E-cadherin gene is frequent and independent of p16INK4A methylation in non-small cell lung cancer: potential prognostic implication. (2004) (23)
Phase 1/2 study of the WT1 peptide cancer vaccine WT4869 in patients with myelodysplastic syndrome (2017) (23)
De novo appearance of der(1;7)(q10;p10) is associated with leukemic transformation and unfavorable prognosis in essential thrombocythemia. (2005) (23)
Chromosome change at 16q22 in nonlymphocytic leukemia: clinical implication on leukemia patients with inv(16) versus del(16). (1988) (23)
Membranous Glomerulonephritis with Nephrotic Syndrome Associated with Chronic Lymphocytic Leukemia (2000) (23)
Malignant pleural mesothelioma produces functional granulocyte-colony stimulating factor. (2001) (23)
ABL-specific tyrosine kinase inhibitor, STI571 in vitro, affects Ph-positive acute lymphoblastic leukemia and chronic myelogenous leukemia in blastic crisis (2001) (22)
Ph-negative chronic myelocytic leukemia with a complex translocation involving chromosomes 7 and 11. (1986) (22)
Cytogenetic findings in adult acute leukemia and myeloproliferative disorders with an involvement of megakaryocyte lineage (1990) (22)
Seven-year follow-up of patients receiving imatinib for the treatment of newly diagnosed chronic myelogenous leukemia by the TARGET system (2010) (22)
Pattern of expression and their clinical implications of the GATA family, stem cell leukemia gene, and EVI1 in leukemia and myelodysplastic syndromes. (1996) (22)
Recurrent endometrial adenocarcinoma with rearrangement of chromosomes 1 and 11. (1986) (22)
Combination of the ABL kinase inhibitor imatinib with the Janus kinase 2 inhibitor TG101348 for targeting residual BCR-ABL-positive cells (2014) (22)
Serum soluble CD44 levels for monitoring disease states in acute leukemia and myelodysplastic syndromes. (1998) (21)
Additional cytogenetic changes and previous genotoxic exposure predict unfavorable prognosis in myelodysplastic syndromes and acute myeloid leukemia with der(1;7)(q10;p10). (2006) (21)
The BCL2L11 (BIM) deletion polymorphism is a possible criterion for discontinuation of imatinib in chronic myeloid leukaemia patients (2013) (21)
Identification and functional signature of genes regulated by structurally different ABL kinase inhibitors (2007) (21)
Clonal T cells of pure red‐cell aplasia (2005) (21)
Expression of telomerase subunits and localization of telomerase activation in hydatidiform mole. (1999) (21)
Validation of cytogenetic risk groups according to International Prognostic Scoring Systems by peripheral blood CD34+FISH: results from a German diagnostic study in comparison with an international control group (2015) (21)
Poly (ADP-ribose) polymerase inhibitors selectively induce cytotoxicity in TCF3-HLF-positive leukemic cells. (2017) (20)
Comparative multi-color flow cytometric analysis of cell surface antigens in bone marrow hematopoietic progenitors between refractory anemia and aplastic anemia. (2000) (20)
Constitutive activation of the ATM/BRCA1 pathway prevents DNA damage-induced apoptosis in 5-azacytidine-resistant cell lines. (2014) (20)
Late appearance of a Philadelphia translocation with minor-BCR/ABL transcript in a t(7;11)(p15;p15) acute myeloid leukemia. (1995) (20)
Deletion (20q) as the sole abnormality in Waldenström macroglobulinemia suggests distinct pathogenesis of 20q11 anomaly. (2006) (20)
Downregulated microRNA-148b in circulating PBMCs in chronic myeloid leukemia patients with undetectable minimal residual disease: a possible biomarker to discontinue imatinib safely (2014) (20)
Overexpression of the homeobox gene DLX-7 inhibits apoptosis by induced expression of intercellular adhesion molecule-1. (2000) (20)
Induction of multiple myeloma bone marrow stromal cell apoptosis by inhibiting extracellular vesicle miR-10a secretion. (2019) (19)
Activity of histone deacetylase inhibitors and an Aurora kinase inhibitor in BCR-ABL-expressing leukemia cells: Combination of HDAC and Aurora inhibitors in BCR-ABL-expressing cells (2013) (19)
Efficacy of MK-0457 and in combination with vorinostat against Philadelphia chromosome positive acute lymphoblastic leukemia cells (2010) (19)
Telomerase and proliferative activity in placenta from women with and without fetal growth restriction. (1999) (19)
Dasatinib preferentially induces apoptosis by inhibiting Lyn kinase in nilotinib-resistant chronic myeloid leukemia cell line (2011) (19)
Transcriptional profiling of human herpesvirus type B (HHV-6B) in an adult T cell leukemia cell line as in vitro model for persistent infection. (2005) (19)
Hepatosplenic αβ T-cell lymphoma with myelodysplastic syndrome. (2005) (19)
Multicenter prospective trial evaluating the tolerability of imatinib for Japanese patients with chronic myelogenous leukemia in the chronic phase: Does body weight matter? (2008) (18)
An improved method for the rapid preparation of 2-amino-4,4a-dihydro-4a,7-dimethyl-3H-phenoxazine-3-one, a novel antitumor agent. (2001) (18)
Clinical efficacy and safety of arbekacin sulfate in patients with MRSA sepsis or pneumonia: a multi-institutional study (2013) (18)
myb oncogene in human hematopoietic neoplasia with 6q- anomaly. (1988) (18)
Telomerase reactivation in leukemia cells. (1996) (18)
The prophylactic effect of itraconazole capsules and fluconazole capsules for systemic fungal infections in patients with acute myeloid leukemia and myelodysplastic syndromes: a japanese multicenter randomized, controlled study (2007) (18)
Cefozopran, meropenem, or imipenem-cilastatin compared with cefepime as empirical therapy in febrile neutropenic adult patients: A multicenter prospective randomized trial. (2015) (18)
Effects of the hedgehog inhibitor GDC-0449, alone or in combination with dasatinib, on BCR-ABL-positive leukemia cells. (2012) (18)
Up-regulated exosomal miRNA-140-3p in CML patients with musculoskeletal pain associated with discontinuation of tyrosine kinase inhibitors (2017) (18)
A rapid monitoring system of human herpesviruses reactivation by LightCycler in stem cell transplantation (2001) (18)
Secondary acute myeloblastic leukemia with a Ph translocation in a treated Wegener's granulomatosis. (1986) (18)
Establishment of a new Philadelphia chromosome-positive acute lymphoblastic leukemia cell line (SK-9) with T315I mutation. (2010) (18)
[Incomplete-form of Behçet disease in a case of monopathic myelodysplastic syndrome presenting as a thrombocytopenia]. (1988) (17)
Re-evaluation of refractory anemia with excess blasts in transformation. (2001) (17)
The tetramerization domain-independent Ras activation by BCR-ABL oncoprotein in hematopoietic cells. (1998) (17)
Clinical and biologic characteristics of CD7+ acute myeloid leukemia. Our experience and literature review. (1994) (17)
Translocation between chromosomes 7 and 11 in nonlymphocytic neoplasia. (1987) (17)
Efficacy and safety of nilotinib in Japanese patients with imatinib-resistant or -intolerant Ph+ CML or relapsed/refractory Ph+ ALL: a 36-month analysis of a phase I and II study (2012) (17)
Interstitial pneumonia possibly due to a novel anticancer drug, TS-1: first case report. (2001) (17)
Acute myeloid leukemia with hypergranular cytoplasm accompanied by t(X;11)(q24;q23) and rearrangement of the MLL gene. (1999) (17)
JAK2V617F mutational status as determined by semiquantitative sequence-specific primer-single molecule fluorescence detection assay is linked to clinical features in chronic myeloproliferative disorders (2007) (17)
Exosomal miRNA Signatures for Late-Onset Acute Graft-Versus-Host Disease in Allogenic Hematopoietic Stem Cell Transplantation (2018) (16)
Copanlisib, a novel phosphoinositide 3-kinase inhibitor, combined with carfilzomib inhibits multiple myeloma cell proliferation (2018) (16)
SH2-containing phosphotyrosine phosphatase SHP-1 is involved in BCR-ABL signal transduction pathways. (1997) (16)
Combined effects of novel heat shock protein 90 inhibitor NVP-AUY922 and nilotinib in a random mutagenesis screen (2011) (16)
Cytogenetic studies in hairy cell leukemia. (1987) (16)
Cytogenetic Risk Features in MDS-Update and Present State. (2009) (16)
Clinical and cytogenetic significance of myelodysplastic syndromes with disease evolution. (1993) (16)
Methylation status of T-cell receptor beta-chain gene in B precursor acute lymphoblastic leukemia: correlation with hypomethylation and gene rearrangement. (1991) (16)
Myelodysplastic syndrome evolving into a myeloproliferative disorder: one disease or two? (1993) (16)
Efficacy and safety of micafungin as an empirical antifungal therapy for suspected fungal infection in neutropenic patients with hematological disorders (2012) (16)
Estimating immunoregulatory gene networks in human herpesvirus type 6-infected T cells. (2005) (16)
JAK2(V617F) mutational status as determined by semiquantitative sequence-specific primer-single molecule fluorescence detection assay is linked to clinical features in chronic myeloproliferative disorders. (2007) (16)
Clinical features of adult acute leukemia with 11q23 abnormalities in Japan: a co-operative multicenter study (2008) (16)
Combining the ABL1 Kinase Inhibitor Ponatinib and the Histone Deacetylase Inhibitor Vorinostat: A Potential Treatment for BCR-ABL-Positive Leukemia (2014) (15)
Monoclonal constitution of neutrophils detected by PCR-based human androgen receptor gene assay in a subset of idiopathic thrombocytopenic purpura patients. (2002) (15)
[A case of vivax malaria with thrombocytopenia suggesting immunological mechanisms]. (1993) (15)
Establishment of a new Hodgkin's cell line (HD‐70) of B‐cell origin (1992) (15)
Interleukin 6 receptor expression by human cord blood‐ or peripheral blood‐derived primitive haematopoietic progenitors implies acquisition of different functional properties (2000) (15)
Increased intracellular activity of matrix metalloproteinases in neutrophils may be associated with delayed healing of infection without neutropenia in myelodysplastic syndromes (2005) (15)
Treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia: a pilot study which raises important questions. (1991) (15)
Late appearance of t(5;12)(q31;p12) in acute myeloid leukemia associated with eosinophilia. (1998) (15)
Activity of omacetaxine mepesuccinate against ponatinib-resistant BCR-ABL-positive cells. (2013) (15)
Chronic myelogenous leukemia with a complex Ph1 translocation in an XYY male. (1984) (15)
Myelodysplastic syndrome accompanied by Addison's disease and multiple autoimmune phenomena: steroid therapy resolved cytopenias and all immune disorders. (2001) (15)
Molecular and clinical investigations in Philadelphia chromosome-negative chronic myelogenous leukemia. (1988) (15)
Detection and quantification of human herpesvirus 6 genomes using bronchoalveolar lavage fluid in immunocompromised patients with interstitial pneumonia. (2001) (15)
[Successful treatment with rituximab in a patient with primary thymic MALT lymphoma complicated with acquired von Willebrand syndrome and Sjögren syndrome]. (2011) (15)
Neutrophil Secondary-Granule Deficiency as a Hallmark of All-Trans Retinoic Acid–Induced Differentiation of Acute Promyelocytic Leukemia Cells (1997) (15)
Cryptic chromosomal anomaly in a patient with acute myeloid leukemia leading to AML1/ETO fusion with unfavorable prognostic factors. (2005) (15)
Efficacy of ponatinib against ABL tyrosine kinase inhibitor-resistant leukemia cells. (2013) (15)
Detection of telomerase activity in exfoliated cancer cells obtained from bile. (1999) (14)
Combined Effects of novel Heat Shock Protein 90 Inhibitor NVP-AUY922 and Nilotinib in a Random Mutagenesis Screen. (2009) (14)
Changes in N-glycosylation of human stromal cells by telomerase expression. (2003) (14)
Application of the international scoring system for myelodysplasia to M.D. Anderson patients [3] (multiple letters) (1997) (14)
Thrombosis can occur at any phase of essential thrombocythemia with JAK2V617F mutation: a single institutional study in Japan (2007) (14)
Two additional cases of acute myeloid leukemia with t(7;11)(p15;p15) having low neutrophil alkaline phosphatase scores. (1993) (14)
Cytogenetic and clinical findings of myelodysplastic syndromes with a poor prognosis. An experience with 97 cases (1992) (14)
EVI1 expression associated with a 3q26 anomaly in a leukemia cell line derived from the blast crisis of chronic myeloid leukemia. (1994) (14)
T-cell receptor gene rearrangement and its expression in human myeloid leukemia cell lines. (1989) (14)
Mechanism of MK-0457 efficacy against BCR-ABL positive leukemia cells. (2009) (14)
Detection method for quantifying global DNA methylation by fluorescence correlation spectroscopy. (2011) (13)
Loss of a Hu-ets-1 allele in human leukemia cell lines ML-1, -2, and -3 with a chromosome change at 11q24. (1987) (13)
Telomere dynamics and cytogenetic changes in human hematologic neoplasias: a working hypothesis. (1997) (13)
Trisomy 10 in acute myeloid leukemia. Three additional cases from the database of the Japan Adult Leukemia Study Group (JALSG) AML-92 and AML-95. (2000) (13)
Assessing the safety and efficacy of ruxolitinib in a multicenter, open-label study in Japanese patients with myelofibrosis (2017) (13)
Derivative (1;7)(q10;p10) in multiple myeloma. A sign of therapy-related hidden myelodysplastic syndrome. (2006) (13)
Compliance with taking imatinib mesylate in patients with chronic myeloid leukemia in the chronic phase. (2009) (13)
CD4+ and CD56+ acute monoblastic leukemia (1990) (13)
Multicenter phase II trial of vitamin K(2) monotherapy and vitamin K(2) plus 1alpha-hydroxyvitamin D(3) combination therapy for low-risk myelodysplastic syndromes. (2010) (13)
Immunogenotypes and clonal culture analysis in B-precursor acute lymphoblastic leukemia. (1992) (13)
Phenylbutazone-induced myelodysplastic syndrome with Philadelphia translocation. (1987) (13)
Immunoglobulin and T cell receptor gene rearrangements in Philadelphia chromosome-positive leukemia: a different involvement pattern in blast crisis and acute leukemia. (1990) (13)
Peripheral T-cell lymphoma together with myelofibrosis with elevated plasma transforming growth factor-β1 (2005) (13)
Human-fms gene is retained in acute lymphoblastic leukemia cells with del(5)(q32). (1987) (13)
Immunosurveillance markers may predict patients who can discontinue imatinib therapy without relapse (2014) (12)
A massive intraventricular thrombosis by disseminated mucormycosis in a patient with myelodysplastic syndrome during deferoxamine therapy. (2003) (12)
Analysis of DNA from cells fixed in Carnoy's solution for cytogenetic study. (1988) (12)
Association of pleural effusion with an early molecular response in patients with newly diagnosed chronic-phase chronic myeloid leukemia receiving dasatinib: Results of a D-First study. (2016) (12)
The C allele of JAK2 rs4495487 is an additional candidate locus that contributes to myeloproliferative neoplasm predisposition in the Japanese population (2012) (12)
Acute myelomonocytic leukemia with double minute chromosomes and a normal karyotype. (1987) (12)
MALT Lymphoma Originating in Breast and Uvula (2001) (12)
[Lung injury associated with bortezomib therapy in Japan]. (2011) (12)
Acute lymphoblastic leukemia with azurophilic granules that contain ultrastructural myeloperoxidase activity (1991) (12)
Hu-ets-1 gene in congenital leukemia with t(11;19)(q23;p13). (1988) (12)
Clinical aspects, cytogenetics and disease evolution in myelodysplastic syndromes. (1996) (11)
Central nervous system involvement in acute nonlymphocytic leukemia with inv(16)(p13q22). (1988) (11)
Characterization of extramedullary tumors in a case of Ph-positive chronic myelogenous leukemia: possible involvement of immature T lymphocytes. (1985) (11)
Double 20q- anomaly in myelodysplastic syndrome. (1992) (11)
Thrombocytopenia Induced by Imatinib Mesylate (Glivec) in Patients with Chronic Myelogenous Leukemia: is 400 mg Daily of Imatinib Mesylate an Optimal Starting Dose for Japanese Patients? (2003) (11)
Neutrophil secondary-granule deficiency as a hallmark of all-trans retinoic acid-induced differentiation of acute promyelocytic leukemia cells. (1997) (11)
Long‐term remission of acquired von Willebrand syndrome associated with multiple myeloma using bortezomib and dexamethasone therapy (2016) (11)
Efficacy of the polo-like kinase inhibitor rigosertib, alone or in combination with Abelson tyrosine kinase inhibitors, against break point cluster region-c-Abelson-positive leukemia cells (2015) (11)
Correction of anaemia in rheumatoid arthritis by recombinant human erythropoietin. (1990) (11)
Chronic myelomonocytic leukemia in a patient with antiphospholipid syndrome: first case report. (1997) (11)
Anaplastic large‐cell lymphoma which showed severe inflammatory status and myelodysplasia with increased VEGF and IL‐6 serum levels after long‐term immunosuppressive therapy (2001) (11)
Correlation between morphology and telomerase activity in cells from exfoliative lung cytologic specimens (2000) (11)
Treatment-free remission after first-line dasatinib treatment in patients with chronic myeloid leukemia in the chronic phase: the D-NewS Study of the Kanto CML Study Group (2020) (11)
Subsequential telomerase activity in exfoliated urinary cells detects recurrent disease in bladder cancer after transurethral resection. (1999) (11)
A patient with pure red cell aplasia and Good's syndrome. (1999) (11)
A Ki-1 (CD30)-positive T (E+, CD4+, Ia+)-cell line, DL-40, established from aggressive large cell lymphoma. (1990) (11)
Overexpression of RUNX3 Represses RUNX1 to Drive Transformation of Myelodysplastic Syndrome (2020) (11)
Expression of hTERT mRNA in a mortal liver cell line during S phase without detectable telomerase activity. (2005) (11)
The methylation status of the major breakpoint cluster region in human leukemia cells, including Philadelphia chromosome-positive cells, is linked to the lineage of hematopoietic cells. (1993) (11)
Prominent pleural effusion possibly due to imatinib mesylate in adult Philadelphia chromosome-positive acute lymphoblastic leukemia. (2006) (11)
Multicenter prospective study of clonal complications in adult aplastic anemia patients following recombinant human granulocyte colony-stimulating factor (lenograstim) administration. (2003) (11)
Differentiation and apoptosis in human malignant melanoma G-361 cells induced by 2-aminophenoxazine-3-one. (2005) (11)
Anti-leukemic activity of axitinib against cells harboring the BCR-ABL T315I point mutation (2015) (10)
Recurrent chromosome changes at 3p21 in Epstein-Barr virus-transformed cells derived from human prolymphocytic leukemia. (1986) (10)
Activity of a novel Aurora kinase inhibitor against the T315I mutant form of BCR‐ABL: In vitro and in vivo studies (2008) (10)
Uncontrolled thrombocytosis in polycythemia vera is a risk for thrombosis, regardless of JAK2V617F mutational status (2007) (10)
Decline in antibiotic enzyme activity of neutrophils is a prognostic factor for infections in patients with myelodysplastic syndrome. (2000) (10)
Cytogenetic findings in a malignant melanoma and its derived cell line. (1986) (10)
[Simultaneous development of factor V inhibitor and autoimmune thrombocytopenia in a patient with dermatomyositis]. (2002) (10)
Combined treatment of leukemia cells with vitamin K2 and 1alpha,25-dihydroxy vitamin D3 enhances monocytic differentiation along with becoming resistant to apoptosis by induction of cytoplasmic p21CIP1. (2005) (10)
Chromosome changes in mycosis fungoides in an XYY male. (1985) (10)
Recurrent der(9;18) in essential thrombocythemia with JAK2 V617F is highly linked to myelofibrosis development. (2008) (10)
Clinical usefulness of transcription-mediated amplification and hybridization protection assay in imatinib-treated chronic myelogenous leukemia patients. (2005) (10)
Successful treatment with imatinib mesylate of hypereosinophilic syndrome (chronic eosinophilic leukemia) with myelofibrosis. (2004) (10)
Genetic variations of bone marrow mesenchymal stromal cells derived from acute leukemia and myelodysplastic syndrome by targeted deep sequencing. (2017) (10)
Breakpoint cluster region rearrangements in chronic myelogenous leukemia with a masked Philadelphia chromosome. (1987) (10)
A sole del(15q) anomaly in post-myelodysplasia acute myeloid leukemia. (1998) (10)
[Chronic myeloid leukemia associated with sustained severe pancytopenia after imatinib mesylate therapy]. (2002) (9)
Myelodysplastic syndrome with trisomy 11 associated with polycythemia vera (1989) (9)
Translocation t(3;4)(q26;q21) in myelodysplastic syndrome with megakaryoblastic proliferation. (1988) (9)
Hypomethylated status, but not RAG-1, is required for T-cell receptor-beta-chain gene rearrangement in acute leukemia cells. (1994) (9)
Combination of Granulocyte Colony-Stimulating Factor and Low-Dose Cytosine Arabinoside Further Enhances Myeloid Differentiation in Leukemia Cells in Vitro (2000) (9)
Monotherapy versus dual therapy based on risk categorization of febrile neutropenic patients. (2004) (9)
Recurrent unbalanced whole-arm t(1;10)(q10;p10) in myelodysplastic syndrome: a case report and literature review. (2007) (9)
Prospective randomized study of cefepime, panipenem, or meropenem monotherapy for patients with hematological disorders and febrile neutropenia (2013) (9)
Sustained complete cytogenetic remission in a patient with chronic myeloid leukemia after discontinuation of imatinib mesylate therapy (2007) (9)
Automated JAK2V617F quantification using a magnetic filtration system and sequence-specific primer-single molecule fluorescence detection. (2007) (9)
Acute myelomonocytic leukemia with inv(16)(p13q22) in an XY/XYY male. (1987) (9)
Cytogenetic changes at 11q11, 11q23, and 17q11 in myelodysplastic syndrome. (1986) (9)
Germline DDX41 mutations define a unique subtype of myeloid neoplasms. (2022) (9)
Evaluation of cardiac iron overload in transfusion-dependent adult marrow failure patients by magnetic resonance imaging. (2009) (9)
Four cases with complex Philadelphia translocations, including one with appearance de novo of a "masked" Ph. (1987) (9)
Telomerase inhibition combined with other chemotherapeutic reagents to enhance anti-cancer effect. (2007) (9)
Hemophagocytic Syndrome Associated with CD8 Positive T-cell Chronic Lymphocytic Leukemia (2004) (8)
A network biology approach evaluating the anticancer effects of bortezomib identifies SPARC as a therapeutic target in adult T-cell leukemia cells (2008) (8)
A 14q+ chromosome in a malignant lymphoma in a patient with Down's syndrome. (1981) (8)
R‐High‐CHOP/CHASER/LEED with autologous stem cell transplantation in newly diagnosed mantle cell lymphoma: JCOG0406 STUDY (2018) (8)
Leukocytosis is linked to thrombosis at diagnosis, while JAK2 V617F mutation is associated with thrombosis during the course of essential thrombocythemia (2008) (8)
Cytogenetic and immunogenotypic alterations of blast crisis cells in chronic myelogenous leukemia independently linked to immunophenotypic expression. (1994) (8)
Enhanced expression of the EVI1 gene in NUP98/HOXA-expressing leukemia cells (2009) (8)
14q+ in Ph-positive chronic myelogenous leukemia. (1986) (8)
Improvement in detecting telomerase activity using silica-based resin treatment: An experience of urine in bladder carcinoma. (1999) (8)
Detection of low allele burden of JAK2 exon 12 mutations using TA-cloning in patients with erythrocytosis. (2009) (8)
Low body weight and body mass index may be associated with musculoskeletal pain following imatinib discontinuation in chronic myeloid leukemia (2017) (8)
T-Cell Receptor β Chain Gene Rearrangement in Acute Myeloid Leukemia Always Occurs at the Allele That Contains the Undermethylated Jβ1 Region (1992) (8)
Variant translocation t(2;21;8)(q36;q22;q22) with RUNX1/CBFA2T1 (AML1/ETO) transcript in a case of acute myelogenous leukemia. (2005) (8)
Involvement of chromosomes 4, 11, and 17 in a case of myelodysplastic syndrome. (1985) (8)
Transformation of severe aplastic anemia into myelodysplastic syndrome with monosomy 7: monoclonal origin detected by HUMARA gene analysis during the aplastic anemia phase. (2000) (7)
Switching to nilotinib in patients with chronic myeloid leukemia in chronic phase with molecular suboptimal response to frontline imatinib: SENSOR final results and BIM polymorphism substudy. (2016) (7)
[A case of eosinophilic pneumonia possibly associated with 5-aminosalicylic acid (5-ASA)]. (2004) (7)
Multiple pulmonary nodules caused by B-cell post-transplant lymphoproliferative disorder after bone marrow transplantation: monitoring Epstein-Barr virus viral load. (2003) (7)
correspondence: PNH‐phenotype cells in patients with idiopathic cytopenia of undetermined significance (ICUS) with megakaryocytic hypoplasia and thrombocytopenia (2010) (7)
Superoxide anion production and expression of cytochrome b 558 by neutrophils are impaired in some patients with myelodysplastic syndrome (1991) (7)
Phase 1 trial of gemtuzumab ozogamicin in combination with enocitabine and daunorubicin for elderly patients with relapsed or refractory acute myeloid leukemia: Japan Adult Leukemia Study Group (JALSG)-GML208 study (2012) (7)
Double-minute chromosomes appearing in a patient with myelodysplastic syndrome with disease evolution. (1995) (7)
Aberrant expression of NK cell receptors in Epstein-Barr virus-positive γδ T-cell lymphoproliferative disorders (2010) (7)
[Lung injury associated with bortezomib therapy in relapsed/refractory multiple myeloma in Japan: a questionnaire-based report from the "Lung Injury by Bortezomib" Joint Committee of the Japanese Society of Hematology and the Japanese Society of Clinical Hematology]. (2006) (7)
[Essential thrombocythemia in transformation to acute leukemia (FAB-M0) as a natural history from myelofibrosis with t(1;7)]. (1997) (7)
Cytogenetic and hematologic findings in acute myelogenous leukemia, M2 according to the FAB classification. (1982) (7)
Natural Killer Cell Lymphoma in the Duodenum (2003) (7)
Multiple lipoma with hyperlipidemia in a multiple myeloma patient treated with bortezomib/dexamethazone. (2010) (7)
MORPHOLOGIC CHANGES OF NEUTROPHILS IN MYELODYSPLASTIC SYNDROME TREATED WITH RECOMBINANT HUMAN GRANULOCYTE COLONY‐STIMULATING FACTOR (1988) (7)
Peripheral T-cell lymphoma together with myelofibrosis with elevated plasma transforming growth factor-beta1. (2005) (7)
Restoration of cardiac function by an iron chelator, deferasirox, in a patient with aplastic anemia and cardiac iron overload (2009) (7)
Direct Demonstration of the Productive Capability of Cytokines at the Single Cell Level in Lung Sarcoidosis Using Multicolor Cytometry (2002) (7)
TRISOMY 11 IN NONLYMPHOCYTIC NEOPLASIA (1988) (7)
Imatinib Mesylate in Combination with Other Chemotherapeutic Agents for Chronic Myelogenous Leukemia (2004) (7)
Frequency of del(12p) is commonly underestimated in myelodysplastic syndromes: Results from a German diagnostic study in comparison with an international control group (2015) (7)
[Assessment of health-related quality of life in cancer outpatients treated with chemotherapy]. (2012) (7)
Cladribine combined with rituximab (R‐2‐CdA) therapy is an effective salvage therapy in relapsed or refractory indolent B‐cell non‐Hodgkin lymphoma (2011) (7)
Clinical Features of Hypereosinophilic Syndrome: FIP1L1-PDGFRA Fusion Gene—Positive Disease is a Distinct Clinical Entity with Myeloproliferative Features and a Poor Response to Corticosteroid (2007) (7)
Trisomy 15 as a single autosomal abnormality in a patient with unclassifiable myelodysplastic syndromes. (2001) (7)
Therapeutic targeting of Aurora A kinase in Philadelphia chromosome-positive ABL tyrosine kinase inhibitor-resistant cells (2018) (6)
Elevated serum soluble CD44 level in sarcoidosis. (2000) (6)
Idiopathic neutropenia with fewer than 5% dysplasia may be a distinct entity of idiopathic cytopenia of undetermined significance (2010) (6)
Effect of the extracellular component of bone marrow mesenchymal stromal cells from healthy donors on hematologic neoplasms and their angiogenesis (2020) (6)
Efficacy of SCH 66336 , a Farnesyl Transferase Inhibitor , in Conjunction with Imatinib against BCR-ABL-positive Cells 1 (2003) (6)
Successful imatinib and arsenic trioxide combination therapy for sudden onset promyelocytic crisis with t(15;17) in chronic myeloid leukemia. (2010) (6)
[Acute megakaryoblastic leukemia associated with Sweet's syndrome, including review of the literature]. (1993) (6)
Anti-Leukemic Effects of Venetoclax on Philadelphia Chromosome Positive Leukemia Cells (2016) (6)
All-trans-retinoic acid induced enrichment of functionally normal neutrophils in vivo in a patient with acute promyelocytic leukemia. (1992) (6)
Cytogenetic and in vitro culture studies on chronic myelomonocytic leukemia (1984) (6)
Cardiac biopsy with intracardiac echocardiographic guidance for successful diagnosis of cardiac lymphoma (2018) (6)
Musculoskeletal pain after stopping tyrosine kinase inhibitor in patients with chronic myeloid leukemia: a questionnaire survey. (2016) (6)
The in vitro effects of all-trans-retinoic acid and hematopoietic growth factors on the clonal growth and self-renewal of blast stem cells in acute promyelocytic leukemia. (1997) (6)
Stromal cell – derived factor-1 / CXCL 12 – induced chemotaxis of T cells involves activation of the RasGAP-associated docking protein p 62 Dok-1 (2004) (6)
Testicular tumor as the first manifestation of B‐lymphoid blastic crisis in a case of Ph‐positive chronic myelogenous leukemia (1988) (6)
Targeting the Hedgehog Signaling Pathway Limits the Self-Renewal of BCR-ABL1 Positive Leukemia Cells: Molecular Mechanisms (2012) (6)
Spliceosome mutations are common in persons with myeloproliferative neoplasm-associated myelofibrosis with RBC-transfusion-dependence and correlate with response to pomalidomide (2020) (6)
Successful prior treatment with dasatinib followed by stem cell transplantation in a patient with CML in blastic crisis with a BCR–ABL mutation (2010) (6)
Combined Effects of a Pan-Aurora Kinase Inhibitor MK-0457 and Dasatinib Against T315I Mutant Form of BCR-ABL: In Vitro and In Vivo Studies. (2007) (6)
ETS1 gene in myelodysplastic syndrome with chromosome change at 11q23. (1990) (5)
[Assessment of psychological distress in cancer outpatients treated with chemotherapy]. (2012) (5)
Association of Peripheral Regulatory T Cells with Achievement of Deep Molecular Response in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia Treated with Dasatinib - the Final Results of D-First Study (2016) (5)
[A case of spinal sarcoidosis complaining of chest and back pain as a first manifestation and mimicking syringomyelia on MRI]. (2002) (5)
IgA-lambda/IgG-kappa biclonal myeloma in which two clones proliferated in individual sites. (2000) (5)
Breast MALT Lymphoma: Potential Relationship Between Hormonal Environment and Female Sex Hormone Receptor Expression in Lymphoma Cells (2001) (5)
Clinical Impacts of Germline DDX41 Mutations on Myeloid Neoplasms (2020) (5)
Percentages of bone marrow blasts and chromosomal changes in patients with refractory anemia help to determine prognoses. (1994) (5)
In vitro cytogenetic effects of recombinant human hematopoietic growth factors on cells derived from myelodysplastic syndromes. (1990) (5)
Myelodysplastic syndrome with Philadelphia-like chromosome without bcr rearrangement. (1988) (5)
An adult case of acute disseminated encephalomyelitis accompanied with measles infection. (2005) (5)
Elevated plasma level of differentiation inhibitory factor nm23-H1 protein correlates with risk factors for myelodysplastic syndrome (2002) (5)
Empirical voriconazole therapy for febrile neutropenic patients with hematological disorders: a prospective multicenter trial in Japan (2013) (5)
Vitamin K 2-induced cell growth inhibition via autophagy formation in cholangiocellular carcinoma cell lines (5)
Inhibitory effect of a nucleoside analog, acyclovir, on leukemia cells. (1996) (5)
A Rare Genetic Polymorphism In C5 Confers Poor Response To The Anti-C5 Monoclonal Antibody Eculizumab In 11 Japanese Patients With PNH (2012) (5)
Gallium-67 scintigraphic findings in a patient with breast lymphoma complicated with Sjögren syndrome (2000) (5)
[Effectiveness of long term administration of humanized anti-interleukin-6 receptor antibody (tocilizumab) for multicentric Castleman's disease with pulmonary involvement]. (2006) (5)
Targeting the Hedgehog Signaling Pathway by Glasdegib Limits the Self-Renewal of MDS-Derived Induced Potent Stem Cells (iPSC) (2017) (5)
Combination therapy with copanlisib and ABL tyrosine kinase inhibitors against Philadelphia chromosome-positive resistant cells (2016) (5)
Double Philadelphia chromosomes in acute lymphocytic leukemia. (2000) (5)
Remission of pure‐red‐cell aplasia associated with operative cure of lung cancer (1999) (5)
Technical improvement in determining telomerase activity in hematologic neoplasias: a possibility of single cell determination of telomerase activity. (1996) (5)
12 Updated cytogenetic risk features in MDS – present state (2009) (5)
Medium pH determines the differentiation of human promyelocytic leukemia cells to basophils or eosinophils by culturing in a protein- and serum-free medium. (1989) (5)
New Prognostic Data on Rare Cytogenetic Abnormalities in MDS: A Collaborative Study of the International Working Group on MDS Cytogenetics (2008) (5)
Establishment of a novel B-lymphoma cell line, CTB-1, with strong Pas antigen expression having chromosomal translocation (14;22). (1997) (5)
Predisposed genomic instability in pre-treatment bone marrow evolves to therapy-related myeloid neoplasms in malignant lymphoma (2019) (5)
A novel phenoxazine derivative suppresses proliferation of human endometrial adenocarcinoma cell lines, inducing G2M accumulation and apoptosis. (2003) (5)
Chronic Lymphocytic Leukemia Complicated by Plasmacytoma Originating from Different Clones (2000) (5)
Two 14q+ chromosomes in malignant lymphoma: crucial cytogenetic changes on 14q. (1985) (4)
Successful cholecystectomy in a patient with aplastic anemia–paroxysmal nocturnal hemoglobinuria during eculizumab treatment (2012) (4)
Multiple myeloma with monosomy 13 developed in trisomy 13 acute myelocytic leukemia: numerical chromosome abnormality during chromosomal segregation process. (2003) (4)
Teriflunomide restores 5-azacytidine sensitivity via activation of pyrimidine salvage in 5-azacytidine-resistant leukemia cells (2017) (4)
Complex translocations derived stepwise from standard t(15;17) in a patient with variant acute promyelocytic leukemia. (2007) (4)
Chronic Renal Insufficiency in Japanese Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH): Improvement with Eculizumab Treatment in the Long-Term Follow-up of the AEGIS Study. (2009) (4)
Combining Effects of the SMO Inhibitor and BCL-2 Inhibitor in MDS-Derived Induced Potent Stem Cells (iPSC) (2017) (4)
[A case of pulmonary intravascular lymphoma treated with CHOP chemotherapy plus rituximab]. (2005) (4)
Use of Real-Time PCR to Monitor Human Herpesvirus 6 (HHV-6) Reactivation (2002) (4)
[Relapse of diffuse large B cell lymphoma to CD20-negative multiple cutaneous tumors immediately after anti-CD20 monoclonal antibody (rituximab) therapy]. (2004) (4)
Estimation of cardiac left ventricular ejection fraction in transfusional cardiac iron overload by R2* magnetic resonance (2010) (4)
Activity of a Novel Aurora Kinase Inhibitor, VE-465, Against T315I Mutant Form of BCR-ABL: In Vitro and In Vivo Studies. (2006) (4)
Comparison between immunogenotypic findings in de novo AML and AML post MDS. (1993) (4)
Maintenance 5-azacytidine therapy by MRD monitoring after allogeneic HSCT in myeloid/lymphoid neoplasms with FGFR1 rearrangement (2019) (4)
Frequent association between trisomy 15 and t(8;21)(q22;q22) in acute myeloid leukemia. (2001) (4)
[The expression pattern of transcription factors (GATA, SCL) and biological characteristics in various leukemia cells]. (1995) (4)
Circulating and Tumor-Infiltrating γδ T Cells in Patients with B-Cell Lymphomas (2000) (4)
[Spontaneous regression of MALT lymphoma of the hard palate accompanied by Sjögren syndrome]. (2003) (4)
Chromatin Regulation by HP1γ Contributes to Survival of 5-Azacytidine-Resistant Cells (2018) (4)
Translocation (5;18) in a patient with myelodysplastic syndrome: refractory anemia with excess blasts in transformation. (2000) (4)
Granulocyte colony-stimulating factor (G-CSF) could enhance Fcγ receptor expression in neutrophils of patients with B-cell lymphoma treated with rituximab (2005) (4)
Quantification of human cytomegalovirus using bronchoalveolar lavage cells in pulmonary complications associated with hematologic neoplasia. (2003) (4)
The translocation (4;12)(q31;q21) in myelofibrosis associated with myelodysplastic syndrome: impact of the 12q21 breakpoint. (2006) (4)
Micafungin-induced hemolysis attack due to drug-dependent antibody persisting for more than 6 weeks. (2010) (4)
[A case of arc welder's lung with ground-glass opacities and progressive massive fibrosis]. (2005) (4)
Therapeutic effects of tyrosine kinase inhibitors and subtypes of BCR-ABL1 transcripts in Japanese chronic myeloid leukemia patients with three-way chromosomal translocations. (2018) (4)
Do leukemia patients with chromosome 16 inversion--inv(16)(p13q22)--have a rare fragile site at 16q22? (1988) (4)
Final Results From SENSOR: Switch to Nilotinib After Molecular Suboptimal Response (SoR) to Frontline Imatinib in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP) (2014) (4)
Vitamin K2 Induces Autophagy and Apoptosis Simultaneously in Leukemia Cells and Bcl-2 Expression Level Determines the Phenotype of Their Cell Death. (2007) (4)
A massive intraventricular thrombosis by disseminated mucormycosis in a patient with myelodysplastic syndrome during deferoxamine therapy. (2003) (4)
Megakaryocytic Maturation is Regulated by Maintaining a Balance Against Cytokine Induced-cell Proliferation: Steel Factor Retards Thrombopoietin-induced Megakaryocytic Differentiation While Synergistically Stimulating Mitogenesis (2000) (4)
Variant t(8;18;21) translocation in acute myeloid leukemia. (1988) (4)
Translocation between chromosomes 1 and 9 in childhood acute lymphoblastic leukemia. (1986) (4)
BIM deletion polymorphism accounts for lack of favorable outcome in Japanese females with follicular lymphoma (2018) (4)
A novel reduced-intensity umbilical cord blood transplantation using a recombinant G-CSF combined with high-dose Ara-C for active myeloid malignancies (2014) (4)
Malignancy: Subsequential Alterations of Telomeric DNA Length Correlate with Cytogenetic Response in Chronic Myeloid Leukemia Treated with Interferon alpha. (1999) (4)
Correction of anemia by recombinant human erythropoietin in a patient with polycythemia vera associated with hemodialysis‐dependent chronic renal failure (1991) (4)
Recurrent chromosomal aberration at 12q15 in chronic idiopathic myelofibrosis with or without JAK2V617F mutation (2007) (4)
Fatal Cyberlindnera fabianii fungemia in a patient with mixed phenotype acute leukemia after umbilical cord blood transplantation (2016) (4)
A Possible Correlation between Interferon-stimulated Gene Expression and Cytogenetic Responses in Chronic Myelogenous Leukemia Patients Treated with α-interferon (1996) (3)
The Analysis of HDAC Inhibitor, Vorinostat Efficacy against Wild Type and BCR-ABL Mutant Positive Leukemia Cells in Monotherapy and in Combination with a Pan-Aurora Kinase Inhibitor, MK-0457 (2008) (3)
The Efficacy of Dual PI3K and mTOR Inhibitor, NVP-BEZ235 against BCR-ABL Positive Leukemia Cells Include ABL Kinase Domain Mutation in Combination with Nilotinib. (2009) (3)
A Phase 1/2 Study of WT1 Peptide Cancer Vaccine WT4869 in Patients with Myelodysplastic Syndromes (MDS) (2015) (3)
Telomerase activity in effusions: a comparison between telomere repeat amplification protocol in situ and conventional telomere repeat amplification protocol assay. (2008) (3)
[Case report; Disseminated Mycobacterium abscessus infection with hemophagocytic syndrome during treatment of chronic lymphocytic leukemia]. (2014) (3)
[Transient hypofibrinogenemia induced by prednisolone in a case of acute lymphoblastic leukemia]. (1989) (3)
Mechanism of Action of MK-0457 Efficacy in Monotherapy and in Combination with Vorinostat in Wild Type and T315I Mutant BCR/ABL Positive Leukemia Cells. (2007) (3)
[Role of bortezomib in the treatment of multiple myeloma]. (2007) (3)
Post-Marketing Surveillance of Bortezomib Treatment for Multiple Myeloma (MM) in Japan: Results of Interim Analysis by the Velcade Japan Proper Use Guideline Committee (2008) (3)
[Rapidly progressive fibrosis and increased CD68-positive cells in the bone marrow at the terminal stage of adult T-cell leukemia accompanied by polycythemia vera]. (2000) (3)
Acute myeloid leukemia with concomitant expression of T-/B-lymphoid antigens and immunogenotypic alterations exhibiting t(7;12)(q32;q24). (1993) (3)
Vitamin K 2-induced antitumor effects via cell-cycle arrest and apoptosis in gastric cancer cell lines (2006) (3)
Increased collagenase activity in macrophages from bronchial lavage as a diagnostic marker of non-small cell lung cancer (2003) (3)
[Telomerase activity and determination of cancer in urological neoplasias using exfoliated urinary cells: in situ TRAP assay and its application]. (1998) (3)
[Successful treatment with interferon-alpha in a case of acute myeloid leukemia with del (20q) following polycythemia vera]. (2005) (3)
Combining ABL1 Kinase Inhibitor, Ponatinib and the Histone Deacetylase (HDAC) Inhibitor Vorinostat: A Potential Treatment for BCR-ABL Positive Leukemia Cells (2011) (3)
In Situ TRAP assay detection of telomerase activity in cytological preparations. (2002) (3)
Non-random chromosomal deletion clustering at 20q in Waldenström macroglobulinemia (2011) (3)
Downregulation of extracellular vesicle microRNA-101 derived from bone marrow mesenchymal stromal cells in myelodysplastic syndrome with disease progression. (2020) (3)
Therapy for Philadelphia chromosome-positive acute lymphoblastic leukemia: possible use of interferon on the basis of some novel concepts. (1993) (3)
Unique radiological features of two cases of primary pulmonary diffuse large B-cell lymphoma (2017) (3)
Endobronchial minute leiomyoma in a patient with malignant lymphoma. (2005) (3)
Chronic myelogenous leukemia with translocations (3q-;9q+) and (17q-;22q+). Possible crucial cytogenetic events in the genesis of CML (2004) (3)
Efficacy and safety of doripenem for sepsis with neutropenia in Japanese patients with hematologic diseases. (2012) (3)
Will a Peripheral Blood (PB) Sample Yield the Same Diagnostic and Prognostic Cytogenetic Data as the Concomitant Bone Marrow (BM) In Myelodysplasia? An International Study Comparing Cytogenetics and Interphase FISH Using Parallel PB and BM Samples (2010) (3)
Amplified EPOR/JAK2 Genes Define a Unique Subtype of Acute Erythroid Leukemia (2022) (3)
Enriched levels of erythropoietin in human umbilical cord blood stimulate hematopoietic progenitor cells. (2002) (3)
Myeloid/Natural Killer Cell Precursor Acute Leukemia Accompanied by Homozygous Protein C Deficiency (2003) (3)
Soluble CD44 level in non-malignant disorders is associated with autoimmune backgrounds. (1999) (3)
T-cell receptor beta chain gene rearrangement in acute myeloid leukemia always occurs at the allele that contains the undermethylated J beta 1 region. (1992) (3)
Estimating Immunoregulatory Gene Networks in Human Herpesvirus Type 6 (HHV-6)-Infected T Cells. (2005) (3)
First Japanese case of sole trisomy 13 anomaly in acute myeloid leukemia. (2000) (3)
Restoration of cytogenetically normal marrow cells after remission of lymphoblastic crisis in a case of Ph positive CML treated with alpha-interferon. (1992) (3)
Age-Related Decrease of Human CD8 + T-Cell Mir-92a Level Correlated with Reduction of naïve T Lymphocyte (2011) (2)
Type I CD36 deficiency in hematologic disorder. (2004) (2)
Circulating and tumor-infiltrating gamma delta T Cells in patients with B-cell lymphomas. (2000) (2)
BCL2L11 (BIM) Deletion Polymorphism Is Associated with Molecular Relapse after ABL Tyrosine Kinase Inhibitor Discontinuation in Patients with Chronic Myeloid Leukemia with Complete Molecular Response (2014) (2)
Measurement of telomerase activity in human hematopoietic cells and neoplastic disorders. (2002) (2)
Philadelphia Chromosome‐positive Chronic Myelogenous Leukemia with Deleted Fusion of BCR and ABL Genes (1990) (2)
Brain abscess in acute myeloid leukemia. (2005) (2)
BCL2L11 (BIM) deletion polymorphism, rather than BIM SNP, is an effective predictor of early molecular relapse after ABL tyrosine kinase inhibitor discontinuation in patients with chronic myeloid leukemia (2015) (2)
De novo appearance of t(7;13)(q10;q33) in the leukemic phase of myelodysplastic syndrome: a case report. (2002) (2)
Epstein-Barr Virus-Associated Inflammatory Pseudotumor-Like Follicular Dendritic Cell Tumor of the Spleen without Recurrence for 3 Years after Splenectomy (2013) (2)
B-cell lineage acute lymphoblastic leukemia with i(7q) and t(9;9)(p22;p24). (1988) (2)
Trisomy 11 acute myeloid leukemia: 5 additional cases from the Japan Adult Leukemia Study Group AML-92 and AML-95 databases. (2000) (2)
A novel non-invasive monitoring assay of 5-azacitidine efficacy using global DNA methylation of peripheral blood in myelodysplastic syndrome (2019) (2)
Safety and Efficacy of the Terminal Complement Inhibitor Eculizumab in Japanese Patients with Paroxysmal Nocturnal Hemoglobinuria: AEGIS Phase II Clinical Study Results. (2008) (2)
[The advantage of an in situ TRAP assay for the detection of telomerase activity using bronchial washings obtained from lung cancer patients]. (1998) (2)
[A lower-leg ulcer during hydroxyurea therapy for essential thrombocythemia]. (1996) (2)
[Diffuse large B-cell lymphoma showing CNS invasion by CD30-positive multinuclear giant cells mimicking the clinical features of progressive multifocal leukoencephalopathy]. (2000) (2)
Abstract C19: DNA demethylation induces upregulation of telomere repeat-containing RNA (TERRA) and downregulation of telomerase activity in human leukemia cells (2011) (2)
[Detection of telomerase activity and its clinical application]. (1997) (2)
Clonal architecture in patients with myelodysplastic syndromes and double or minor complex abnormalities: Detailed analysis of clonal composition, involved abnormalities, and prognostic significance (2018) (2)
High Frequencies Of Switching To 2nd TKIs and Failure To Maintain Standard Imatinib Dose In Japanese CML Patients With BIM Genetic Variants (2013) (2)
Author Correction: Lineage-specific RUNX2 super-enhancer activates MYC and promotes the development of blastic plasmacytoid dendritic cell neoplasm (2019) (2)
Detection of Epstein-Barr virus in a pyothorax-associated lymphoma with T-cell phenotype. (2002) (2)
Molecular implications of Ph (+) myelodysplastic syndrome. (1988) (2)
Disparity Between the Macroglobulin-Producing Components of 2 Cases of Follicular Lymphoma With Waldenström’s Macroglobulinemia (2001) (2)
抗CD20モノクローナル抗体(rituximab)療法後，短期間にCD20陰性の多発性皮膚腫瘤で再発したびまん性大細胞型B細胞リンパ腫 (2004) (2)
Chromosomes and Chromosomal Instability in Human Cancer (2017) (2)
Marked telomere fluctuation of leukocytes during graft-versus-host disease in allogeneic stem cell transplantation. (2005) (2)
Targeting the Hedgehog Signaling Pathway By PF-04449913 Limits the Self-Renewal of MDS-Derived Induced Potent Stem Cells (iPSC): Molecular Mechanisms (2015) (2)
Myelodysplastic Syndrome with Erythroid Hypoplasia is a New Clinical Entity Responsive to Cyclosporin A Therapy (2002) (2)
Potential of a sphingosine 1-phosphate receptor antagonist and sphingosine kinase inhibitors as targets for multiple myeloma treatment (2022) (2)
Effect of combined deferasirox and 5-azacytidine treatment on human leukemia cells in vitro (2015) (2)
[Molecular relapse of chronic myeloid leukemia after discontinuation of imatinib mesylate for maintaining complete molecular response for more than 2 years]. (2009) (2)
Activity of the Stemness Inhibitor, BBI608, on the Self-Renewal of BCR-ABL1 Positive Leukemia Cells: Molecular Mechanisms (2014) (2)
HIV positivity may not have a negative impact on survival in Epstein-Barr virus-positive Hodgkin lymphoma: A Japanese nationwide retrospective survey. (2018) (2)
Clinical efficacy and safety of biapenem for febrile neutropenia in patients with underlying hematopoietic diseases: a multi-institutional study (2011) (2)
Syndromes International Scoring System for Evaluating Prognosis in Myelodysplastic (2010) (2)
Relapse of chronic myeloid leukemia-chronic phase 14 years after allogeneic hematopoietic stem cell transplantation (2008) (2)
[Refractory idiopathic thrombocytopenic purpura which responded to protein A column]. (1989) (2)
DLX-7 homeobox gene regulates c-myc and GATA-1 gene expression in different stages respectively. (1999) (2)
Karyotypically independent clones with del(11q) and trisomy 10 in acute myeloid leukemia: trisomy 10 may appear as an additional change (2008) (2)
GDC-0449, the Small Molecule Inhibitor of Hedgehog-Gli Pathway for the Treatment of BCR-ABL Positive Leukemia Cells and In Combination with Dasatinib (2010) (2)
[CD56- and CD4-positive non-Hodgkin's lymphoma of probable T-cell origin]. (2001) (2)
The t(4;9)(q11;q33) fuses CEP110 to KIT in a case of acute myeloid leukemia (2011) (2)
Translocation (4;9)(q11;q33), a new rearrangement in acute myeloid leukemia with central nervous system involvement. (2006) (2)
[Treatment-free molecular remission achieved by combination therapy with imatinib and IFNα in CML with BIM deletion polymorphism relapsed after stop imatinib]. (2015) (1)
[Subacute necrotizing lymphadenitis showing lymphatic blockade-mediated acute respiratory failure]. (2006) (1)
Ponatinib Safety and Efficacy in Japanese Patients with Philadelphia Positive Leukemia: Update of a Phase 1/2 Study (2014) (1)
Effective and well tolerated treatment with melphalan and dexamethasone for primary systemic AL amyloidosis with cardiac involvement. (2009) (1)
Translocation (10;21)(q21;q22) in myelodysplastic syndrome. (2007) (1)
[Molecular diagnosis and therapeutic strategy for Philadelphia chromosome-positive acute leukemia]. (1994) (1)
Isolated erythrocythemia: a distinct entity or a sub-type of polycythemia vera? (2008) (1)
Spontaneous Regression of Pulmonary Infiltration of Adult T-Cell Leukemia/Lymphoma (2007) (1)
5q-syndrome in Japan (2011) (1)
Telomeres in Myelodysplastic Syndrome and Its Related Disorders: Does Telomere Length Reflect Stem Cell Turnover in Clonal Hematopoietic Disorders? (2003) (1)
Refractory anemia with ringed sideroblasts with a low IPSS score progressed rapidly with de novo appearance of multiple karyotypic abnormalities and into acute erythroleukemia (AML-M6A). (2000) (1)
Efficacy of Ponatinib Against ABL Tyrosine Kinase Inhibitor Resistant Leukemia Cells (2011) (1)
Prognostic Impact of Rare Single Abnormalities in Myelodysplastic Syndromes (2015) (1)
Targeting the Hedgehog Signaling Pathway in Therapy-Resistant BCR-ABL1 Positive Leukemia with Ponatinib (2011) (1)
Comparison of reduced-intensity/toxicity conditioning regimens for umbilical cord blood transplantation for lymphoid malignancies (2020) (1)
Change in a complex translocation involving band 7q34 and 9p‐ in a case of t‐cell lymphoblastic lymphoma (1990) (1)
Activity of the Histone Deacetylase Inhibitor, Vorinostat, Against BCR-ABL Positive Leukemia Cells with Random Mutagenesis and In Combination with Nilotinib (2010) (1)
[A suspected case of Wegener granulomatosis accompanied with pachymeningitis and white matter lesions]. (2005) (1)
Plasma Mir-92a Levels in Multiple Myeloma Correlate with T-Cell-Derived Mir-92a and Restored in Bortezomib Responder (2011) (1)
[Successful treatment with rituximab for autoimmune hemolytic anemia associated with chronic lymphocytic leukemia]. (2013) (1)
Activation Levels of Natural Killer Cells and CD8 + T Cells Correlate Highly with Sustained Complete Molecular Response After Discontinuation of Imatinib in Chronic Myeloid Leukemia Patients (2012) (1)
Molecular Characteristics That Predict Response to Azacitidine Therapy (2019) (1)
Targeting The Dopamine Receptor Signaling Limits The Self-Renewal Of BCR-ABL1 Positive Leukemia Cells: Molecular Mechanisms (2013) (1)
[Telomere, telomerase and cytogenetic changes in myelodysplastic syndromes]. (1998) (1)
Reply to Kremer M et al., The JAK2 V617F mutation occurs frequently in myelodysplastic/myeloproliferative diseases, but is absent in true myelodysplastic syndromes with fibrosis (2006) (1)
[Hematopoietic cell death and leukemia]. (2009) (1)
Dual HDAC and PI3K Inhibitor, CUDC-907 Alone or in Combination with ABL Tyrosine Kinase Inhibitor Against ABL Tyrosine Kinase Inhibitor Resistant Leukemia Cells (2015) (1)
[Primary diffuse large B-cell lymphoma of the esophagus]. (2004) (1)
Anti-Leukemic Activity of Axitinib Against Cells Harboring the BCR-ABL Point Mutation (2015) (1)
Mechanism of Drug Resistance to Dasatinib (BMS-354825) and Imatinib in Chronic Myelogenous Leukemia Cells. (2006) (1)
Lower Plasma Mir-92a Levels Predict Shorter Progression-Free Survival In Newly Diagnosed Symptomatic Multiple Myeloma Patients (2013) (1)
[Development of in situ TRAP assay detecting telomerase activity in cell]. (1998) (1)
C021 The oral iron chelator deferasirox represses signaling through the mTOR in myeloid leukemia cells by enhancing expression of REDD1 (2009) (1)
A chromosome survey of 42 cases of chronic myelogenous leukemia: significance of the Philadelphia translocation. (1984) (1)
Antitumor Activity of Phosphoinositide 3-Kinases Inhibitor, Copanlisib in Multiple Myeloma Cells (2014) (1)
144 Detection of telomerase activity in cell in myelodysplastic syndromes: Application of in situ telomeric repeat amplification protocol (TRAP) (1997) (1)
Diagnostic contribution of sputum cytology in a case of non-Hodgkin lymphoma. (2007) (1)
EPOR/JAK/STAT Signaling Pathway As Therapeutic Target of Acute Erythroid Leukemia (2021) (1)
P741: DDX41 MUTATIONS DEFINE A UNIQUE SUBTYPE OF MYELOID NEOPLASMS. (2022) (1)
Lineage-Specific RUNX2 Super-Enhancer Activates MYC Via Translocation (6;8) to Promote the Development of Blastic Plasmacytoid Dendritic Cell Neoplasm (2018) (1)
Translocation (2;16)(p11;q22) and trisomy 22 in acute myelogenous leukemia (FAB M2) with bone marrow eosinophilia. (1991) (1)
Der(1;7)(q10;p10) Presents with a Unique Genetic Profile and Frequent ETNK1 Mutations in Myeloid Neoplasms (2021) (1)
Abstract 2904: EGFR-targeted gold liposome for molecular imaging and therapy on NSCLC cells (2012) (1)
An association between telomere shortening and disease evolution patterns in MDS (1994) (1)
Immunological Control of Chronic Myeloid Leukemia Leading to Treatment-Free (2014) (1)
Anti-Leukemic Activity of Phosphoinositide 3-Kinase Inhibitor, Copanlisib in ABL Tyrosine Kinase Resistant Leukemia Cells (2014) (1)
[Hypereosinophilic syndrome complicated by myelofibrosis]. (1999) (1)
Near-hexaploid Ph-positive acute myeloid leukemia with major-BCR/ABL transcript. (1996) (1)
Molecular Signatures That Predict Response to Azacitidine Treatment for Myelodysplastic Syndromes (2017) (1)
Post-azacitidine clone size predicts outcome of patients with myelodysplastic syndromes and related myeloid neoplasms. (2023) (1)
Activity Of Omacetaxine Mepesuccinate Against Ponatinib Resistant Philadelphia Chromosome Positive Leukemia Cells (2013) (1)
A long-survival case of systemic AL amyloidosis with nephrotic syndrome. (2002) (1)
Hidden FLT3-D835Y clone in FLT3-ITD-positive acute myeloid leukemia that evolved into very late relapse with T-lymphoblastic leukemia (2018) (1)
Comparative Pharmacokinetic/Pharmacodynamic Profiles in Japanese and Caucasian Patients with Transfusional Hemosiderosis Receiving Treatment with Deferasirox (Exjade®, ICL670). (2006) (1)
The Incidence of Pleural Effusion on Dasatinib Treatment Is Associated with CD56 Positive Cell Values One Month after Commencing Dasatinib and Achievement of an Early Molecular Response in Newly Diagnosed Chronic Myeloid Leukemia Patients: Results of a D-First Study (2014) (1)
Bone Marrow Cytogenetic Complete Remission Achieved by Interferon-α Plus Cytarabine Ocfosfate Therapy in a Patient With Chronic Myelogenous Leukemia During Extramedullary Blast Crisis (2002) (1)
Therapeutic Potential Of Targeting Sphingosine-1-Phosuphate and Sphingosine Kinases In Multiple Myeloma (2013) (1)
P-060 The DNA methylation index of peripheral blood is a predictive marker for resistance to azacytidine in MDS patients (2013) (0)
[Induction of Ph-negative normal clone and long-term survival by combined treatment with G-CSF plus middle dose cytosine arabinoside for patients with chronic myeloid leukemia in blastic transformation]. (1998) (0)
Abstract 5627: Involvement of pyrimidine metabolism pathway in 5-azacytidine resistance. (2013) (0)
Effect of the extracellular component of bone marrow mesenchymal stromal cells from healthy donors on hematologic neoplasms and their angiogenesis (2020) (0)
Depsipeptide (FK228) Preferntially Induces Apoptosis in Acute T-Cell Leukemia Cell Lines Mediated by CD45 and Src Kinase. (2006) (0)
Short communication Recurrent unbalanced whole-arm t(1;10)(q10;p10) in myelodysplastic syndrome: a case report and literature review (2007) (0)
ASCORBATE FOR THE TREATMENT OF IDIOPATHIC THROMBOCYTOPENIC PURPURA (1990) (0)
[A family with a sister and brother affected by acute leukemia (author's transl)]. (1982) (0)
BCR-ABL1-positive chronic myeloid leukemia emerging in a patient with secondary myelofibrosis harboring the JAK2-V617F mutation. (2017) (0)
Topic: AS04-MDS Biology and Pathogenesis/AS04b-Clonal diversity & evolution (2021) (0)
Combining Effects of the SMO Inhibitor and Jak1 Inhibitor in Terminal Differentiation of MDS-Derived Induced Potent Stem Cells (iPSC) (2016) (0)
Very late relapse with rapid BCR‐ABL1 elevation after more than seven years of treatment‐free remission with undetectable molecular residual disease in chronic myeloid leukaemia (2019) (0)
Abstract PR12: Extracellular miR-92a secreted by human leukemia cells enhances endothelial cell migration in HUVECs (2011) (0)
Autophagy and Apoptosis Are Induced Simultaneously in Leukemia Cells by Vitamin K2. (2006) (0)
Unrelated clones in AML/MDS - characterisation and prognostic relevance (2010) (0)
[Autoimmune phenomena during interferon-alpha therapy for hematopoietic disorders]. (2003) (0)
Autophagy Induction of Acute Myeloid Leukemia (AML) Cells after Treatment with Low Dose-Cytarabine (Ara-C) and Enhanced Cytocidal Effect on AML Cells by Combined Treatment with Ara-C Plus Lenograstim. (2007) (0)
Abstract LB-519: Chemotaxis of acute promyelocytic leukemia cells toward CXCL12 is involved in ATRA syndrome and the requirement of chemotherapy during Induction therapy with ATRA (2012) (0)
Effectiveness of dose reduced THP-COP like therapy with the addition of etoposide for elderly DLBCL patients. (2017) (0)
[Bladder carcinoma in a case of multiple myeloma IgG (kappa) treated with cyclophosphamide: review of literature]. (1988) (0)
Targeting Insulin-like Growth Factor in Multiple Myeloma: Novel Strategies in the Treatment of Proteasome Inhibitor Resistant Cells (2018) (0)
Specific Inhibition of hTERT by shRNA Sensitizes for Imatinib Mesylate in BCR-ABL-Positive Cells. (2004) (0)
[Chronic myeloid leukemia/chronic myeloproliferative disorders]. (2007) (0)
Abstract 2275: A novel heat shock protein 90 inhibitor, NVP-AUY922, enhances the antitumor effect of imatinib via autophagy on imatinib-resistant CML cells (2012) (0)
Cancer Therapy : Preclinical See related commentary by Dao and Tyner , p . 1309 Combination of Ponatinib with Hedgehog Antagonist Vismodegib for Therapy-Resistant BCR-ABL 1 – Positive Leukemia (2013) (0)
[Invasive aspergillosis and pulmonary alveolar proteinosis in acute myeloid leukemia]. (2002) (0)
Myelodysplastic Syndromes with Myelofibrosis May Be a Target for the JAK2 V617F Tyrosine Kinase Mutation. (2005) (0)
Localization of telomerase activation using in situ trap and expression of telomerase subunits in hydatidiform mole (1998) (0)
[A retrospective analysis of neurotoxicity induced by vinca alkaloids combined with azole anti-fungal agents in hematological malignancies]. (2011) (0)
[A case of chronic myelogenous leukemia with a pericentric inversion of the heterochromatic region of chromosome No. 1 (author's transl)]. (1982) (0)
Technical report A rapid monitoring system of human herpesviruses reactivation by LightCycler in stem cell transplantation (2001) (0)
T-Cell Receptor Chain Gene Rearrangement in Acute Myeloid Leukemia Always Occurs at the Allele That Contains the Undermethylated J / l Region (2007) (0)
Loss of a Hu-ets-l AlÃ-elein Human Leukemia Cell Lines ML-1 ,2 , and-3 with a Chromosome Change at Ilq 24 * (2006) (0)
A unique breast involvement detected by MRI‐DWIBS in T cell acute lymphoblastic leukemia (2019) (0)
Fatigue and impaired quality of life in patients with paroxysmal nocturnal hemoglobinuria (PNH) is associated with hemolysis, but not with anemia (2012) (0)
Activity of histone deacetylase inhibitors and an Aurora kinase inhibitor in BCR-ABL-expressing leukemia cells: Combination of HDAC and Aurora inhibitors in BCR-ABL-expressing cells (2013) (0)
Cytogenetic classification according to IPSS/-R is possible from peripheral blood in patients with Myelodysplastic Syndromes (2016) (0)
Hypoxia-induced paclitaxel resistance in cervical cancer modulated by miR-100 targeting of USP15 (2023) (0)
MOLECULAR GENETIC SIGNIFICANCE OF MYELODYSPLASTIC SYNDROME (1999) (0)
Topic: AS07-Singular Entities/Subtypes/AS07e-Chronic myelomonocytic leukemia and overlap syndromes (MDS/MPN): UNDERSTANDING CMML BIOLOGY BY INTEGRATIVE ANALYSIS OF EXOME SEQUENCING, RNA SEQUENCING, AND METHYLOME IN A LARGE PATIENT COHORT (2023) (0)
Diffuse large B‐cell lymphoma resembling a metastatic liver tumour (2015) (0)
Cytogenetics in myelodysplastic syndromes. (2011) (0)
[Donor leukocyte transfusion in early relapsed acute lymphoblastic leukemia after allogenic bone marrow transplantation]. (2000) (0)
Targeting peroxisome proliferator-activated receptors: a novel strategy for Philadelphia chromosome-positive leukemia cells (2017) (0)
[Clinical epidemiology]. (2001) (0)
Detection of BIM ( BCL 2 L 11 ) Polymorphic Variants in Chronic Myeloid Leukemia by Q-Invader Assay and Their Clinical Significance (2014) (0)
IgA-A/IgG-K Biclonal Myeloma in which Two Clones Proliferated in Individual Sites (2007) (0)
[Clinical implications of chromosome analysis in myelodysplastic syndrome]. (1993) (0)
[A case of non-specific chronic inflammatory tracheo-bronchial stenosis]. (1986) (0)
[Identification of propionibacterium acnes in a case with stage III pulmonary sarcoidosis involving hepatosplenic disease]. (2006) (0)
PS1259 LONG-TERM FOLLOW-UP OF JCOG0406 STUDY: INTENSIVE IMMUNOCHEMOTHERAPY (R-HIGH CHOP/CHASER) FOLLOWED BY HIGH-DOSE CHEMOTHERAPY (LEED) WITH AUTO-PBSCT IN UNTREATED MANTLE CELL LYMPHOMA (2019) (0)
[Acute myelomonocytic leukemia with inv (16) (p13q22) relapsed in central nervous system with an orbital tumor]. (1988) (0)
Presence of Philadelphia (Ph) chromosome-negative cells in Ph-positive chronic myelogenous leukemia. (1990) (0)
A case of terminal deoxynucleotidyl transferase- and Philadelphia chromosome-positive acute leukemia with heterogenous blasts, which responded poorly to vincristine and prednisolone therapy. (1983) (0)
[Sideroblastic anemia]. (1998) (0)
Molecular Landscape of Myeloid Neoplasms with Der(1;7)(q10;p10) (2022) (0)
[Molecular biologic study in chronic myelogenous leukemia and its related disorders]. (1988) (0)
PF400 ANTI-LEUKEMIA EFFECT OF DISULFIRAM AND ASCORBATE IN ABL TYROSINE KINASE INHIBITOR RESISTANT LEUKEMIA CELLS (2019) (0)
Relationship between telomerase activity, proliferative activity and apoptosis in placenta of normal and abnormal prengancy (1998) (0)
Erratum to: Clinical efficacy and safety of biapenem for febrile neutropenia in patients with underlying hematopoietic diseases: a multi-institutional study (2011) (0)
[Human herpesvirus-6 pneumonitis following autologous peripheral blood stem cell transplantation]. (2018) (0)
Transcriptional Profiling of Epstein-Barr Virus (EBV) Genes and Host Cellular Genes in Nasal NK/T-Cell Lymphoma and Chronic Active EBV Infection. (2005) (0)
Seven-Year Follow-up of Patients Receiving Imatinib for the Treatment of Chronic Myelogenous Leukemia by the TARGET System (2010) (0)
Efficacy and Safety of Micafungin as An Empirical Antifungal Therapy for Suspected Fungal Infection in Patients with Hematological Disorders. (2008) (0)
Erratum: Clinical efficacy and safety of biapenem for febrile neutropenia in patients with underlying hematopoietic diseases: A multi-institutional study (Journal of Infection and Chemotherapy DOI: 10.1007/s10156-010-0075-3) (2011) (0)
Vitamin K2 (VK2) Monotherapy and VK2 Plus D3 Combination Therapy in Low-Risk Myelodysplastic Syndrome: A Prospective Japanese Study. (2005) (0)
[Targeted therapy in hematologic neoplasia: overview]. (2007) (0)
Abstract 6168: Implementation and adoption of a web tool to support precision diagnostic and treatment decisions for patient with myelodysplastic syndromes (2023) (0)
Clonal Evolution of Therapy-Related Myeloid Neoplasm Analyzed Sequentially By Targeted Deep Sequencing Using Bone Marrow Cells (2018) (0)
[Prognostic aspects of myelodysplastic syndromes]. (2007) (0)
Ki-ras-2 in acute lymphoblastic leukemia cells with chromosome change at 12p12. (1988) (0)
Interleukin 1 Beta As a Promising Therapeutic Target in ABL Tyrosine Kinase Inhibitor Resistant Chronic Myeloid Leukemia Cells (2018) (0)
Combined Effects of a Pan-ABL1 Kinase Inhibitor, Ponatinib and Dasatinib Against T315I Mutant Forms of BCR-ABL1: In Vitro and In Vivo Studies (2011) (0)
Telomerase activity during carcinogenesis in the bronchus. (2002) (0)
[Acute myelomonocytic leukemia with inv(16) (p13q22) developed in a case of ovarian cancer]. (1988) (0)
46 Recent developments in the prognostic classification for MDS: Results of The International Risk Analysis Workshop (1997) (0)
[Simultaneous occurrence of multiple myeloma and acute myeloid leukemia without previous chemotherapy]. (1982) (0)
Extracellular Vesicles (EVS) Released by Bone Marrow Stromal Cells Show a Distinct Mirna Profile in High-Risk MDS Patients (2017) (0)
Efficacy Of The Polo-Like Kinase Inhibitor, Rigosertib Alone Or In Combination With ABL Tyrosine Kinase Inhibitor Against BCR-ABL-Positive Leukemia Cells (2013) (0)
A Case of Massive Atelectasis Possibly Due to Idiopathic Bronchial Hemorrhage (2002) (0)
Characterization of granulocyte-colony stimulating factor producing lung cancer (2000) (0)
[New horizon of chronic myelogenous leukemia]. (2007) (0)
with GATA-1, GATA-2, and stem cell leukemia gene expression post-myelodysplasia acute myeloid leukemia: possible association Ecotropic virus integration site-1 gene preferentially expressed in (2011) (0)
P-61 Telomere attrition of lymphocytes in myelodysplastic syndrome: Correlation with clinical findings (2005) (0)
Comparative risk factor analysis in Japanese patients with myelodysplastic syndromes (1994) (0)
A novel strategy for ABL tyrosine kinase inhibitor resistant ph-chromosome positive leukemia cells (2017) (0)
Identification and Functional Significance of Genes Regulated by Structurally Different ABL Kinase Inhibitors. (2005) (0)
[An effective antilymphocyte globulin treatment in a case of aplastic anemia]. (1988) (0)
P-66 Characteristics ofmyelodysplastic syndromes with der(1;7)(q10;p10): Report of 19 cases from Japan (2005) (0)
Leukemic phase of intermediate non-Hodgkin's lymphoma with cells showing different matured stages in invaded various organs. (1992) (0)
[Molecular implication of Ph positive leukemias: treatment with alpha-interferon in Ph positive acute leukemia]. (1993) (0)
Determination of donor-derived killer immunoglobulin-like receptor (KIR) by sequential genotyping in hematopoietic stem cell-transplanted patients (2010) (0)
[New horizon of chronic myelogenous leukemia]. (2007) (0)
Increased NK Cells and Decreased CD3+CD8+CD62L+ T Cells in CML Patients Who Sustained Complete Molecular Remission After Discontinuation of Imatinib (2011) (0)
Combined Effects of Novel Heat Shock Protein 90 Inhibitor NVP-AUY922 and Nilotinib against Mutant Forms of BCR-ABL (2008) (0)
[A cold agglutinin disease, difficult to distinguish from paroxysmal cold hemoglobinuria]. (2003) (0)
Amyloid Angiopathy-related Severe Hemorrhage with Multiple Myeloma (2017) (0)
[Development trend in new therapeutic approaches for anemia]. (2008) (0)
Safety and efficacy of the terminal complement inhibitor eculizumab in Japanese patients with paroxysmal nocturnal hemoglobinuria: AEGIS Phase II clinical study results (2012) (0)
Molecular investigations in philadelphia chromosome negative chronic myeloid leukemia presence of the ph negative clone with bcr rearrangements (1988) (0)
P-77 Itraconazole capsules versusfluconazole capsules for anti-fungal chemoprophylaxis in patients with myelodysplastic syndromes or acute myeloid leukemia with multilineage dysplasia (2005) (0)
Telomerase Inhibition with a Novel G-Quadruplex-Interactive Agent, Telomestatin: In Vitro and In Vivo Studies in Acute Leukemia. (2004) (0)
Simultaneous occurrence of der(1;7)(q10;p10) and t(14;18)(q32;q21) in non-Hodgkin's lymphoma: der(1;7) will appear as a secondary change in lymphoid neoplasia (2005) (0)
Lineage-specific RUNX2 super-enhancer activates MYC via a chromosomal translocation and promotes the BPDCN (2019) (0)
Post-azacitidine clone size predicts long-term clinical outcome of patients with myelodysplastic syndromes and related myeloid neoplasms (2021) (0)
POST-AZACITIDINE CLONE SIZE PREDICTS LONG-TERM OUTCOME OF PATIENTS WITH MYELODYSPLASTIC SYNDROMES AND RELATED MYELOID NEOPLASMS (2023) (0)
Activity of ABT-737, an Inhibitor of BCL-2 Family Proteins, in Imatinib- or Dasatinib-Resistant CML Cells: Involvement of BCL-2 Family Proteins for Drug Resistance. (2005) (0)
A multicenter, phase II study of R-THP-COP therapy for elderly patients with newly diagnosed, advanced-stage, indolent B-cell lymphoma (2021) (0)
Two Additional Acute Nonlymphocytic Leukemia Patients with a Sole Chromosome Abnormality of Trisomy 4. (1990) (0)
Clinical Analysis of Adult Acute Leukemia with Rearrangements of the 11q23/MLL: Multicenter Co-Operative Study. (2006) (0)
[A case of primary pulmonary cavitation with thin smooth walls in sarcoidosis]. (2004) (0)
.tive Philadelphia Acute Lvmph o blas tic Leukemia: Possible Use of Intekfeton on the Basis of Some Novel Concepts (1993) (0)
[Deletion of 13q in aplastic anemia after treatment with anti-thymocyte globulin]. (2004) (0)
P042 Cytogenetic and morphologic features of myelodysplastic syndrome with less than 5 blasts to delineate idiopathic cytopenia with undetermined significance (2009) (0)
O-70 Vitamin K2 therapy in low-riskmyelodysplastic syndrome: A prospective Japanese study (2005) (0)
P744: UNBALANCED TRANSLOCATION DER(1;7)(Q10;P10) AS A DISTINCT SUBTYPE IN MYELODYSPLASTIC SYNDROMES (2022) (0)
[Presence of Gaucher-like cells in a case of Ph1-positive chronic myeloid leukemia with lymphoid-myeloid crisis]. (1988) (0)
75 Telomere dynamics in myelodysplastic syndromes (1997) (0)
Unrelated Clones In Myelodysplastic Syndromes and Acute Myeloid Leukemia Characterization and Prognostic Relevance (2010) (0)
The Efficacy of Histone Deacetylase Inhibitor, Vorinostat against BCR-ABL Positive Leukemia Cells Include ABL Kinase Domain Mutation in Monotherapy and in Combination with Dasatinib (2008) (0)
Pseudothrombocytes detected by two-color flowcytometry in acute lymphoblastic leukemia (ALL-L3). (2006) (0)
P-54 Telomere length control bytelomere binding proteins, TRF1, TRF2 and POT1, in myelodysplastic syndrome (2005) (0)
[Successful treatment of acute myelomonocytic leukemia developed from essential thrombocythemia with cytarabine plus etoposide]. (2004) (0)
WT-1 Expression Level In BM Is The Great Prognostic Marker In Three Of Classification IPSS, WPSS, and Latest Revised IPSS(IPSS-R) (2013) (0)
A Shorter Halving Time for BCR-ABL transcript Reduction Is a Novel Predictor of Molecular Response Achievement in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia (CML-CP) Patients Treated with Dasatinib: Results of D-First Study (2014) (0)
[Molecular-target therapy of Ph-positive leukemia by imatinib (tyrosine kinase inhibitor)]. (2003) (0)
PO004 Cytogenetic and clinical features of secondary myelodysplastic syndrome/acute myeloid leukemia: a single institutional study in Japan (2007) (0)
[An autopsied case of CML in which masked Ph1 was observed following myeloid crisis through lymphoid crisis (author's transl)]. (1981) (0)
Telomeric Repeat-Containing RNA Terra in Myelodysplastic Syndrome: Utility of Cell-Free Terra Packaged in Extracellular Vesicles (2017) (0)
Coexistence of myelodysplastic syndromes and plasma cells disorders. a cytogenetic review (2010) (0)
Depsipeptide (FK228) Preferentially Induces Apoptosis in BCR/ABL-Expressing TF-1 Cells. (2005) (0)
[Implication of Ph1 translocation in chronic myelogenous leukemia]. (1987) (0)
Nilotinib Following Molecular Suboptimal Response (SoR) To Imatinib In Japanese Patients (pts) With Chronic Myeloid Leukemia In Chronic Phase (CML-CP): 12 Month Follow-Up From The SENSOR Study (2013) (0)
Successful MPB Therapy Followed By Bortezomib Maintenance for Non-Transplant Eligible Patients with Newly Diagnosed Multiple Myeloma: Japanese Phase 2 Study - Broad-J Study (2017) (0)
A modified landmark method for dealing with an event observed during a follow-up period. (1995) (0)
Clinical impact of uncontrolled complement activity in Japanese non-transfused patients with paroxysmal nocturnal hemoglobinuria (2012) (0)
Analysis of Histone Deacetylase Inhibitor, FK228, Effect on Chronic Myelogenous Leukemia Cell Line. (2004) (0)
ABL gene fuses BCR during t(20;22) results in Philadelphia-negative, but BCR/ABL-positive chronic myeloid leukemia (2002) (0)
Paradoxically decreased intracellular collagenase activity in macrophages from bronchoalveolar lavage fluid in current smokers and patients with obstructive ventilatory disorder. (2004) (0)
255 A novel global DNA methylation detection by fluorescence spectroscopy, a possible evaluation system of demethylating status for myelodysplastic patients (2011) (0)
[Clinical management of tumor lysis syndrome]. (2012) (0)
[HIV-related multiple non-Hodgkin lymphomas]. (2008) (0)
Abstract 2305: Hypoxia modulates tumor exosomes, which function as mediators of angiogenesis. (2013) (0)
C005 Prognostic impact of the proportion of aberrant metaphases in patients with a primary myelodysplastic syndrome (2009) (0)
P-47 Lack of mutations of the humantelomerase RNA gene (HTERC) in myelodysplastic syndromes (2005) (0)
Combining ABL1 Kinase Inhibitor, Imatinib and the Jak Kinase Inhibitor TG101348: A Potential Treatment for Residual BCR-ABL Positive Leukemia Cells (2012) (0)
The new era of imatinib mesylate (2004) (0)
A PHASE II STUDY OF THP (PIRARUBICIN)‐COP THERAPY IN PATIENTS WITH NEWLY DIAGNOSED ADVANCED PTCL: THP‐3 STUDY OF JAPAN HEMATOPOIETIC MALIGNANCY CLINICAL STUDY GROUP (2019) (0)
[Successful induction chemotherapy after colectomy in a case of acute lymphoblastic leukemia associated with obstructive ileus caused by sigmoid colon carcinoma]. (1990) (0)
P-033 A possible association between 5-azacytidine sensitivity and epigenetic modulation of telomeres in human leukemia cells (2013) (0)
[Refractory anemia: the entity and recent findings]. (1998) (0)
Activity of the Aurora Kinase Inhibitor, MLN8237 (alisertib) Alone or in Combination with Ponatinib Against Imatinib-Resistant BCR-ABL-Positive Cells (2012) (0)
[Intrafamilial epidemic of meningococcal meningitis]. (2000) (0)
A Phase II Study of THP-COP (pirarubicin, cyclophosphamide, vincristine and prednisolone) in Patients with Newly Diagnosed Advanced Peripheral T-Cell Lymphoma: THP-3 Study of Japan Hematopoietic Malignancy Clinical Study Group (HMCSG) (2017) (0)
Erratum to: Assessing the safety and efficacy of ruxolitinib in a multicenter, open-label study in Japanese patients with myelofibrosis (2017) (0)
[Acute myelomonocytic leukemia with inv(16) (p13q22) developed in an XY/XYY male]. (1987) (0)
Analysis of 3 Year Post Marketing Surveillance of Eculizumab in Japan (2014) (0)
ETS-1 gene in human leukemia cells. (1988) (0)
Cefozopran, meropenem, or imipenemecilastatin compared with cefepime as empirical therapy in febrile neutropenic adult patients: A multicenter prospective randomized trial (2015) (0)
A possible correlation between interferon-stimulated gene expression and cytogenetic responses in chronic myelogenous leukemia patients treated with alpha-interferon. (1996) (0)
Germline Risks and Clinical Impacts of DDX41 Mutations in Myeloid Malignancies (2022) (0)
[Pulmonary Kaposi's sarcoma successfully diagnosed by transbronchial lung biopsy]. (2001) (0)
Assessment of the International Prognostic Scoring System for Determining Chemotherapeutic Indications in Myelodysplastic Syndrome: Japanese Retrospective Multicenter Study (2005) (0)
[Analysis of the c-fms gene in hematopoietic neoplasia with changes of chromosome 5]. (1988) (0)
Cefozoplan, Meropenem, or Imipenem-Cilastatin Versus Cefepime As an Empirical Therapy in High Risk Febrile Neutropenic Adult Patients: A Multicenter Prospective Randomized Trial (2012) (0)
Adult T-cell leukemia showing different immunophenotypes in invaded organs. (2001) (0)
Lineage-specific RUNX2 super-enhancer activates MYC and promotes the development of blastic plasmacytoid dendritic cell neoplasm (2019) (0)
Additional Cytogenetic Changes and Prior Genotoxic Exposure Predict Unfavorable Prognosis in Myelodysplastic Syndromes and Acute Myeloid Leukemia with der(1;7)(q10;p10). (2005) (0)
Clinical implication of JAK2V167F-positive chronic myeloproliferative disorders: semi-quantitative Analysis of Mutated allele by sequence-specific primer-single molecule fluorescence detection assay (2007) (0)
Post-Treatment Clone Size Predicts Survival Independently of IPSS-R and Response after Azacitidine Therapy for MDS. (2020) (0)
A clustered dense body in a patient with splenic lymphoma with villous lymphocytes. (2001) (0)
[Molecular biology and FAB classification]. (1992) (0)
[Immunogenotypic and clonal culture studies in Philadelphia chromosome-positive acute leukemia]. (1991) (0)
A Clinical Pharmacology and Exploratory Study of Azacitidine Administered Subcutaneously or Intravenously In Japanese Patients with Myelodysplastic Syndrome (2010) (0)
Long-term efficacy and safety of eculizumab in Japanese patients with PNH: AEGIS trial Yuzuru KanakuraKazuma OhyashikiTsutomu ShichishimaShinichiro Okamoto • Kiyoshi AndoHaruhiko NinomiyaTatsuya KawaguchiShinji NakaoHideki Nakakuma • Jun-ichi NishimuraTaroh KinoshitaCamille L. BedrosianKeiya OzawaMi (2013) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Kazuma Ohyashiki?

Kazuma Ohyashiki is affiliated with the following schools:

Kazuma Ohyashiki's Academic­Influence.com Rankings

Kazuma Ohyashiki's Degrees

Similar Degrees You Can Earn

Why Is Kazuma Ohyashiki Influential?

Kazuma Ohyashiki's Published Works

Published Works

What Schools Are Affiliated With Kazuma Ohyashiki?

Kazuma Ohyashiki's AcademicInfluence.com Rankings